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1. INTRODUCTION 
 
 
For millenia the consumption of alcoholic beverages has contributed to the pleasure of 
eating and drinking in many cultures of the world. In addition to livening up the social 
atmosphere, light alcohol drinking may also have beneficial effects on human health. An 
example of this is the “J-shaped” relation between the risk of coronary heart disease and 
alcohol intake. Overall morbidity is lower among those who drink lightly than those 
who drink more heavily or who do not drink at all (Klatsky, 1994). While the optimal or 
non-injurious levels of alcohol intake are difficult to estimate, they have been thought to 
be quite low, approximately 10-19 g/day for men and less than 10 g/day for women 
(Kalant and Poikolainen, 1999). When taken in excess, alcohol has devastating effects 
on human health by leading to breakdown of bodily functions and damaging virtually 
every organ of the body. Alcohol use may also lead to alcoholism, which can be defined 
as “the extreme dependence on excessive amounts of alcohol associated with a 
cumulative pattern of deviant behaviours”.  
 
Excessive alcohol consumption is known to increase the risk of developing several 
diseases of the liver, which are principally “fatty liver”, hepatitis, and cirrhosis. Also 
well-known are cases of alcohol-induced acute or chronic pancreatitis. Ethanol itself has 
been thought to be the hepatotoxic agent, but since only a relatively small proportion of 
heavy drinkers develop the most severe forms of liver damage, it is probable that other 
factors are also involved (Lindros, 1995). The pathogenesis of alcohol-induced 
pancreatic injury is still obscure, although major hypotheses so far have emphasized 
ethanol-induced changes in the pancreatic ductal system or the toxic effects of ethanol 
on  pancreatic exocrine metabolism (Singh and Simsek, 1990). 
 
Less is known about other multiple gastrointestinal symptoms and organ toxicities 
associated with heavy alcohol use. There is evidence of small intestinal dysfunction 
after chronic alcohol consumption, including increased mucosal permeability, 
promotion of bacterial overgrowth, altered gut motility, and impaired salt and water 
absorption. This can lead to diarrhea, dyspepsia, nausea, and finally to malnutrition, 
which are common findings among actively drinking alcoholics (Persson, 1991). The 
association between alcohol consumption and certain digestive tract neoplasia has also 
been well established. Epidemiological studies have shown that cancers of the mouth, 
esophagus, and larynx are associated with alcohol consumption and that the risk 
increases in a dose-dependent manner (Doll et al., 1999). Likewise, high alcohol intake 
is a suspected risk factor for colorectal cancer. Although this subject has been debated, 
two different meta-analyses both reach the conclusion that alcohol leads to a small but 
significantly increased cancer risk, especially for the left colon and the rectum (Kune 
and Vitetta, 1992; Longnecker et al., 1990). 
 
The mechanism for the increased cancer risk associated with alcohol consumption is not 
clear, but has been believed to be at least in part due to the carcinogenic action of the 
first metabolite of ethanol, acetaldehyde (IARC, 1985, 1999). This notion is strongly 
supported by recent epidemiological studies which show that GI-tract cancer risk is 
markedly increased among heavy drinking Asian individuals with a genetically deficient 
ability to remove acetaldehyde (Yokoyama et al., 1998). The reactivity of acetaldehyde 
may also involve it in promoting organ toxicity other than malignant transformation.  
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During recent years it has become evident that the colonic microbes take part in ethanol 
metabolism not only by fermenting sugars to ethanol, but also by oxidizing exogenous 
ethanol to acetaldehyde (Jokelainen, 1997; Salaspuro, 1996, 1997). Similarly, oral 
microflora have been shown to produce high concentrations of acetaldehyde from 
ethanol (Homann et al., 1997a). Ethanol oxidation and consequent acetaldehyde 
production by gut microbes occurs at ethanol concentrations that are relevant to those 
after moderate alcohol drinking (Homann et al., 1997a; Jokelainen et al., 1994). 
Furthermore, since the capacity of intestinal mucosa and flora to metabolise 
acetaldehyde further is limited, acetaldehyde accumulates locally in the areas of the 
digestive tract covered by microbes (Koivisto and Salaspuro, 1996; Nosova et al.,  
1998). 
 
Due to its high reactivity, toxicity and carcinogenicity, acetaldehyde can be expected to 
cause organ damage wherever it exists at high concentrations. Therefore, microbial 
ethanol oxidation and consequent acetaldehyde production may have important 
implications for the pathogenesis of symptoms and organ toxicity associated with 
excessive alcohol use. Understanding the mechanisms behind alcohol-induced 
gastrointestinal morbidity is helpful in their management and a prerequisite for their 
prevention. The present study thus investigates the enzymes involved in microbial 
ethanol oxidation, its contribution to total ethanol elimination, and possible regulatory 
factors, and is intended to obtain evidence about possible organ toxicity related to 
microbial acetaldehyde production. 
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2. REVIEW OF THE LITERATURE 
 
 
2.1. BIOCHEMICAL CHARACTERISTICS OF ETHANOL AND 
ACETALDEHYDE 
 
Ethyl alcohol (CH3CH2OH; Mol wt 46.1) is the accurate term for ethanol. The 
synonyms ”alcohol and alcoholic beverages” are also commonly used in the literature 
and in colloquial language. The term “alcohol” is, however, slightly misleading, since 
several other alcohols, like methanol, also exist. In the context of this thesis the terms 
ethanol and alcohol are used as synonyms, and alcoholic beverages means any products 
that contain ethanol.  
 
Ethanol is obtained by fermentation of carbohydrates contained in a variety of natural 
products. Preparation of absolute anhydrous ethanol (percentage by weight 
approximately 99.5%) for research purposes needs special distillation procedures. The 
density of absolute ethanol at 20 C compared with water at 4 C is 0.789. The melting 
point of absolute ethanol is -114.1 C and the boiling point is 78.5 C. Important 
characteristics of ethanol are its small molecular size and miscibility in water in any 
proportion. However, ethanol is only slightly soluble in fat; tissue fat takes up about 4% 
of the amount of ethanol dissolved in an equal volume of water (IARC, 1988; Wallgren 
and Barry III, 1970).  
 
A number of different systems are used to indicate the ethanol content, dosage, solutions 
for administration and concentration in body fluids. To indicate ethanol content or 
concentration of ethanol in alcoholic beverages, percentage by weight (% w/w) or 
volume (% v/v) are used. The dosage for scientific reasons should preferably be 
expressed as weight of ethanol given per unit of body weight of the test organism (g/kg 
body weight). For solutions to be administered, when the basis is pure ethanol, the most 
convenient way is to prepare solutions that contain a known weight of ethanol in a given 
volume of the final solution. The clearest expression is thus percentage weight by 
volume or % w/v. Percentage by volume (%v/v) can also be employed. There are 
several ways of expressing ethanol concentrations in body fluids and in in vitro 
incubations. Concentrations are normally stated in millimoles per litre (mM) or as a 
mille scale o/oo. One per mille equals one gram ethanol per litre, or 0.1 % w/v, or 21.7 
mM. In some scientific publications, blood alcohol is also given as “mg %”, indicating 
milligrams ethanol per 100 ml. Table 1 shows the equivalence of units used in 
measuring concentrations of ethanol in body fluids. 
 
Units used in this book are as follows: blood and body fluid ethanol concentrations are 
generally given as mM. Dosages given are expressed as g/kg body weight, and solutions 
for that purpose either in %w/v or %v/v.      
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 Table 1. Equivalence of units used in measuring   
 concentration of ethanol in body fluids    
 (Modified from Wallgren and Barry III, 1970) 
 
  Per cent (%) Per mille (‰) mg/100 ml  mM  
 g/100 ml      mg/ml or g/l   (“mg%) 
 0.001 0.01 1 0.217 
        0.01 0.1 10 2.17 
     0.1 1.0 100 21.7 
    0.2 2.0 200 43.4 
    0.3 3.0 300 65.1 
 0.4 4.0 400 86.8 
 0.5 5.0 500 108.5 
 0.6 6.0 600 130.2 
 0.7 7.0 700 151.9 
 0.8 8.0 800 173.6 
 0.9 9.0 900 195.3 
 1.0 10.0 1,000 217.0 
 
 
Acetaldehyde (CH3CHO; Mol wt 44.1) is a byproduct of the organic chemicals 
industry. It also occurs in vehicle exhaust and the smoke of tobacco cigarettes. For our 
research purposes the main source of acetaldehyde formation is intracellular oxidation 
of ethanol. The density of pure acetaldehyde at 20 C is 0.778, and its melting point is -
123.5 C and the boiling point 20.1 C. Like ethanol, acetaldehyde is miscible with water 
and most common organic solvents (IARC, 1985, 1999). Since the concentrations of 
acetaldehyde in this thesis are given either as µM or µmol/l, which are equivalent, an 
acetaldehyde concentration of 100 µM equals 4.4 mg/l.  
 
 
2.2 HUMAN ORAL AND GASTROINTESTINAL MICROFLORA - AN 
OVERVIEW 
 
Salivary microbial flora 
 
The mouth cannot be regarded as a single, uniform environment. The majority of 
investigations on the flora of the mouth have been concerned either with saliva or dental 
plaque. For the aims and purposes of this thesis, the most important flora in the mouth is 
that of the saliva. The reason for this is that ethanol is present in saliva in concentrations 
comparable to those of blood ethanol (Jones, 1979), and saliva is in close contact with 
the mucosa of the oropharynx and esophagus.  
 
The salivary flora is derived from the dislodgement of microorganisms from various 
locations in the oral cavity i.e. the teeth, tongue, cheek and pharyngeal mucous 
membranes (Herrera et al., 1988; Nolte, 1977). Adult human saliva contains 
approximately 6 x 109 microorganisms per millilitre (Nolte, 1977). Streptococci, the 
facultative anaerobic Gram-positive organisms, have been isolated from all sites in the 
mouth and comprise a large proportion of the normal oral flora. On average, 
Streptococci represent about 45% of the total cultivable flora from saliva and the term 
Streptococcus viridans group is often used to generalize these bacteria. It includes, 
however, at least 5 different species, of which Streptococcus salivarius appears to 
comprise a significant proportion. Anaerobic streptococcus forms part of the anaerobic 
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flora of the oral cavity (Marsh, 1980; Nolte, 1977).  Aerobic Gram-positive 
Staphylococci, Stomatococcus, and Micrococci have also been isolated from the oral 
cavity and saliva, but not in large quantities. Corynebacterium, Lactobacillus and 
Actinomyces are Gram-positive rods frequently found in human oral flora, and 
consisting of aerobic, facultative anaerobic and strictly anaerobic species. Aerobic 
Neisseria and strictly anaerobic Veillonella, which are Gram-negative cocci, have been 
isolated in low numbers from most sites in the oral cavity and saliva. The majority of 
aerobic or facultatively anaerobic Gram-negative rods fall into the genus Haemophilus 
(Marsh, 1980). Yeasts are aerobic microorganisms that can be isolated from 
approximately 40% of clinically healthy mouths, and Candida albicans is the most 
dominant species (Stenderup, 1990). Most anaerobic oral Gram-negative rods belong to 
the genus Bacteroides (Marsh, 1980).  
 
Flora of the stomach and small intestine 
 
All bacteria able to live as commensals in the human body are killed by incubation at 
pH values below 3. The pH of the normal resting gastric juice is below 3 and so the 
normal resting gastric juice is bacteria free. However, even in young normochlorhydric 
persons, the lumen is not bacteria-free for the whole day. During a meal the gastric acid 
is buffered, allowing swallowed salivary bacteria to survive or even to proliferate. 
However, when the pH returns to less than 3 these swallowed organisms are killed (Hill, 
1995). As a consequence, a resident bacterial flora in the stomach can only occur when 
gastric acid secretion is impaired to the point that the pH does not fall below 3-4, even 
in the resting stomach. Thus, most of the organisms found in the stomach very likely 
represent the most acid-resistant components of the oral flora; Lactobacillus, 
Streptococcus viridans, Neisseria, Staphylococcus, Bacteroides and Peptostreptococcus 
are the genera best represented (Gustafsson, 1982; Hill, 1985). Impairing gastric acid 
secretion leads, however, to bacterial overgrowth in the stomach (Drasar et al., 1969). 
Conditions resulting in achlorhydria or hypochlorhydria include for example gastric 
surgery that includes vagotomy, pernicious anaemia or chronic atrophic gastritis, or the 
prolonged use of histamine 2 receptor antagonists or proton pump inhibitors. It has been 
shown that treatment with antacids or cimetidine raises bacterial counts 10- to 100-fold 
(Snepar et al. 1982). Moreover, it has been shown that gastric and duodenal bacterial 
overgrowth is considerably higher in patients treated with omeprazole compared to 
cimetidine. This was explained by the more pronounced inhibition of gastric acid 
secretion (Thorens et al., 1996). 
 
An apparent exception is infection with Helicobacter pylori. This organism colonizes 
the mucosa below the mucin barrier and is able to resist local acid secretion via its 
urease activity. Since the mucosal barrier protects the organisms from luminal acid they 
are able to proliferate in a locally pH-controlled environment (Marshall et al., 1990). 
 
When the gastric contents enter the small bowel they are mixed with large volumes of 
biliary and pancreatic secretions, many of which are bactericidal and help to sterilize 
this material. Furthermore, there is extensive fluid secretion from the bowel mucosa, 
which serves to flush the crypts and prevent colonization of the mucosal layer. Small 
bowel transit time is only two to four hours, an additional barrier to small bowel 
colonization. For these reasons the normal small bowel is in general almost sterile or 
contains a very sparse flora of transient organisms (Hill, 1985, 1995). Anaerobes only 
slightly outnumber facultative organisms, Streptococci, Lactobacillus, Veillonella,  
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yeasts, and Staphylococci being found (Justesen et al., 1984). A resident flora can only 
establish itself in areas of stasis, such as diverticulae, surgical blind loops, coeliac 
disease or in tropical sprue (Hill, 1995). Additionally, as with the stomach, the use of 
drugs to diminish gastric acid secretion has also been shown to lead to bacterial 
overgrowth in the jejunal fluid (Shindo et al., 1998). 
 
In the distal ileum, mean bacterial counts are much higher than in the proximal small 
intestine, and the flora more closely resembles colonic flora with higher counts of 
coliforms and Bacteroides. It should be noted that “coliform” is a common name for 
those bacteria belonging to the Enterobacteriaceae family that are able to ferment 
lactose. It includes Escherichia coli and most other Enterobacteriaceae species 
belonging to the normal human flora. Since the terminal ileum appears to be a 
“transitional” zone between the relatively sterile upper small intestine and the colon 
with its rich bacterial population, its flora being similar to that of the caecum, although 
in smaller numbers, and probably results at least in part from reflux through the 
ileocaecal valve (Hill, 1995). 
 
Large intestinal microflora 
 
Several problems confront anyone attempting to define the composition of the intestinal 
microflora in different parts of the large intestine. More than 400 different bacterial 
species and approximately 1014 individual bacteria inhabit a human colon (Goldin, 
1990). It has been estimated that a complete bacteriological description of one faecal 
sample takes a year of laboratory work (Simon and Gorbach, 1984). The normal colonic 
flora is usually inferred from the composition of the faecal flora. However, bacterial 
counts vary throughout the large bowel, and the numbers found in faecal specimens may 
not accurately represent counts found in other locations. Moreover, faecal flora 
represents only the luminal flora and the flora associated with mucosal epithelia differs 
markedly (next chapter). Bentley et al. (1972) compared the microflora of the transverse 
colon, caecum, and terminal ileum with the microflora of stool samples. The highest 
bacterial counts were obtained from stool samples. Microbial counts in the transverse 
colon and caecum were on average 2-4 logarithmic values lower than in stool samples, 
and counts were even lower in the terminal ileum. Although there were substantial 
numerical differences between stool cultures and cultures from various locations in the 
large bowel, there did not appear to be marked qualitative differences in the flora.  
 
A characteristic of the luminal flora of the large intestine is that anaerobes outnumber 
aerobes by a factor of 100 to 1000 (Cummings, 1983; Simon and Gorbach, 1986). 
Several reports indicate that five genera account for the majority of the viable forms of 
anaerobic bacteria: Bacteroides, Eubacterium, Bifidobacterium, Peptostreptococcus and 
Fusobacterium. Various aerobic, microaerophilic and facultative anaerobic organisms 
are also present in the colonic flora, the most common being Enterobacteriaceae, 
Enterococcus, Lactobacillus, and yeasts (Salminen et al., 1995). Altogether, it has been 
estimated that bacteria account for 35-50% of the volume of the contents of the human 
colon. This equals 41-57% of the dry weight of colonic contents (Salminen et al., 1995).   
 
The faecal flora is not the same in any two individuals. The concentration of each 
bacterium can vary by as much as 100 000-fold between individuals within a given 
group (Moore et al., 1978). It is, however, widely accepted that the faecal flora in one 
individual is relatively stable over time (Bornside, 1978). The effect of diet on faecal 
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flora is controversial. It has been shown that there are differences in the faecal flora 
between people consuming quite different diets (Aries et al., 1969; Finegold et al., 
1974), but the effect of dietary alterations has turned out to be extremely difficult to 
demonstrate (Hill and Drasar, 1975). There is a consensus that dietary alterations change 
the composition of the faecal flora only slightly and very slowly or not at all (Bornside, 
1978; Hill and Drasar, 1975). Studies of the metabolic activity of the flora based on 
measurements of bacterial enzymes have, however, revealed changes in the colonic flora 
as a function of diet (Simon and Gorbach, 1984). Although faecal flora in general is 
quite stable over prolonged periods of time, hospitalisation, for example, has been 
shown to lead to rapid colonization by the specific E. coli serogroups associated with a 
particular institute (Simon and Gorbach, 1984). The use of certain antimicrobial agents 
is also a potent way to alter colonic microflora. 
 
The colonic mucosa-associated flora (MAF) 
 
Studies on animals have suggested the existence of a specific mucosal-dependent flora 
in the colon (Savage, 1970). In contrast to the enormous amount of literature on the 
bacteria of faeces, there is little data on the bacteriology of the mucosa-associated flora 
(MAF) in humans. Nevertheless, analysis of biopsy material and specimens of surgically 
excised tissue have shown that human colon has a flora associated with the mucosa 
which is distinct from that of the gut lumen. It is reproducible, stable, and responds to 
antibiotic treatment differently from that of the lumen (Bleday et al., 1993; Hill, 1995; 
Nelson and Mata, 1970; Peach et al., 1975). One of the most important features of MAF 
is that it has approximately equal representation of aerobic and anaerobic organisms 
compared with the luminal flora (Marks et al., 1979; Peach et al., 1975). Facultative 
anaerobes belonging to the Enterobacteriaceae family are well represented in the MAF 
(Marks et al., 1979; Peach et al., 1978), whereas anaerobes have been shown to be 
mainly Bacteroides species (Poxton et al., 1997).   
 
The mechanisms by which microbes adhere to the mucosal membrane depend on a 
variety of factors. Dietary fibres may influence the composition of the bacterial flora by 
providing nutrients or altering the environmental conditions including peristaltic rate or 
mucous composition (Savage, 1978). The normal function of the absorptive epithelium 
presumably depends upon a suitable oxygen tension, which in turn depends upon blood 
flow, arterial oxygen content, and oxygen utilization. One of the earliest studies 
measuring oxygen tension in the gut lumen was done by using domestic duck. Oxygen 
tension (PO2) was found to be about 25 mm Hg close to the mucosal villi area, while it 
was 50 times lower in the centre of the lumen (Crompton et al., 1965). Studies with 
dogs have shown that the intestinal mucosa has an oxygen tension of the order of 40 mm 
Hg, which is between a quarter and a third of that in air and approximately similar to 
that of the venous blood (Hamilton et al., 1968). One study with humans showed about 
the same magnitude of oxygen tension in mucosa of the gut (45 mm Hg) (Dawson et al., 
1965).  In contrast, flatus usually has a PO2 of less than 15 mm Hg (Askevold, 1956). 
Utilization of O2 by colonic bacteria is thought to lower the intraluminal PO2 to the 
level present in flatus. Moreover, it has been shown that conventional rats have a lower 
intraluminal PO2 and higher pCO2 than germ-free rats. This is probably because of the 
consumption of O2 and the production of CO2 by bacterial metabolism (Bornside et al., 
1973). Taken together, the amount of oxygen diffused to the colonic mucosa may be the 
predominant factor explaining the proportionally higher counts of aerobic and 
facultative organisms in the MAF than in the luminal flora.  
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It has been suggested that the importance of the microbes colonizing the mucosa is that 
they modulate the function of the mucosal barrier. Disturbing the balance of MAF has 
been shown to lead to alterations in paracellular pathways at the level of the tight 
junctions, thereby increasing mucosal permeability (Spitz et al., 1994). Moreover, 
intestinal microorganisms are able to oxidize and reduce many types of organic 
compound. Consequently, it has been shown that the MAF is of importance in 
regulating enzyme levels in the intestinal mucosa of the rat (Hietanen and Hänninen, 
1971). This is of great importance, since aerobic and facultative anaerobic microbes are 
able to oxidize ethanol to acetaldehyde. Because the ratio of aerobes to anaerobes is 
approximately 1:1 in the vicinity of the mucosa, this could be an important site for 
bacterial ethanol metabolism in the gut. It has, indeed, been shown that conventional 
rats have significantly higher acetaldehyde levels in the mucosa of the rectum and 
caecum than germ-free rats after ethanol administration (Seitz et al., 1990). 
  
The effect of antimicrobial agents on human faecal flora with special reference 
to ciprofloxacin and metronidazole 
 
The administration of an antibiotic is undoubtedly the most potent way of altering the 
markedly stable microflora of the human body. Since many antimicrobial agents cause 
changes in the colonic flora, the severity of which depends largely upon the 
concentration of the agent in the luminal contents, factors other than the width of the 
antibacterial spectrum may be of importance for the ecological consequences of 
antibiotic treatment in the colon (Norrby, 1986). Accordingly, the faecal microflora can 
be influenced by orally taken antimicrobial agents because of incomplete absorption, 
secretion into the bile, or secretion from the intestinal mucosa. Parenteral antimicrobial 
agents which are secreted into the bile or from the intestinal mucosa can also cause 
significant disturbances in the large intestinal microflora (Nord et al., 1986).  
 
Ciprofloxacin is a broad spectrum fluoroquinolone antimicrobial agent. The primary 
mechanism of the action of ciprofloxacin is the inhibition of bacterial DNA gyrase, 
which disrupts bacterial DNA replication. After oral administration ciprofloxacin has an 
approximate bioavailability of 70% and maximum plasma concentrations are achieved 
in 1 to 2 hours. The drug has a large apparent volume of distribution (2.1 to 5 L/kg after 
oral or intravenous administration) and becomes concentrated in many body tissues and 
fluids, including bile, kidney, liver, gallbladder, prostate and lung tissue. Ciprofloxacin 
is excreted largely unmetabolised in the urine and faeces, although small amounts of 
metabolites have also been detected (Davis et al., 1996). Furthermore, ciprofloxacin is 
partly eliminated through the intestinal wall (Rohwedder et al., 1990), and the 
concentrations of ciprofloxacin in the faeces and intestinal mucosa are higher than the 
corresponding serum levels (Brismar et al., 1990). This transintestinal elimination 
pattern may explain the particular ability of this drug to modify the colonic flora.  
 
The effect of ciprofloxacin in vivo on the composition of faecal flora has been studied 
extensively in healthy volunteers. The usual dosage regimens have been from 600 to 
1000 mg/day for five or more days. These studies clearly demonstrate the marked 
reduction or complete eradication of Enterobacteriaceae. This occurs rapidly, usually 
within 3 days of commencing therapy. Following discontinuation of the therapy, these 
bacteria return to pretreatment concentrations within 3 to 4 weeks. The effects of 
ciprofloxacin on Staphylococci and Enterococci are not as dramatic or consistent as on 
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the Enterobacteriaceae, although many studies report significant reduction in one or 
both of these groups. Generally, ciprofloxacin does not affect the levels of total 
anaerobic flora. However, where anaerobic rods, Fusobacterium and Bacteroides 
species have been analysed separately, some studies have demonstrated decreases in 
faecal levels (Campoli-Richards et al., 1988).  
 
Metronidazole was originally introduced to treat Trichomonas vaginalis, but is now 
used for the treatment of anaerobic and protozoal infections. Metronidazole is 
bactericidal through toxic metabolites which cause DNA strand breakage. 
Metronidazole given orally is absorbed almost completely, with bioavailability of 
>90%. Metronidazole is distributed widely and has low protein binding (<20%). The 
volume of distribution at steady state in adults is 0.5 to 1.1 L/kg. Metronidazole reaches 
60 to 100% of plasma concentrations in most tissues studied, and is extensively 
metabolised by the liver into 5 metabolites. The majority of metronidazole and its 
metabolites are excreted into urine and faeces, with less than 12% excreted unchanged 
into urine (Lamp et al., 1999).  
 
Metronidazole is most active in vitro against gram-negative obligately anaerobic bacilli 
such as Bacteroides, including the B. fragilis group and Fusobacterium. (Bergan, 1985). 
Although metronidazole and its active metabolites are found in the faeces and also in 
colonic mucosa, there is normally little suppression of indigenous colonic flora with 
metronidazole therapy. This has been thought at least partly because of the degradative 
reduction of the drug by bowel flora under the anaerobic conditions in the colon 
(Finegold, 1980).  However, studies done with mice have shown that high doses of 
metronidazole decreases obligate anaerobes in vivo in the large intestinal flora and this 
leads to a consequent increase in certain aerobic species. Brook and Ledney (1994) 
found that the mean number of facultative anaerobes rose significantly from day 6 
(p<0.05), whereas strict anaerobes fell significantly (p<0.05) during the treatment with 
metronidazole compared to controls. In another study metronidazole treatment 
selectively eliminated strictly anaerobic bacteria with a concomitant 100-fold increase in 
aerobic and facultative bacteria (Wells et al., 1987). Similarly, in the human studies, the 
number of Bacteroides species has been shown to decrease and the number of E. coli 
and faecal Streptococci to increase in the faeces of patients with Crohn’s disease during 
treatment with metronidazole (Krook et al., 1981a). Among healthy human volunteers, 
however, the count of Bacteroides species was unchanged at the end of metronidazole 
treatment, but there was a significant increase in the faecal Streptococci count (p=0.03) 
and an almost significant increase in E. coli (p=0.06) (Krook, 1981). These 
dissimilarities in metronidazole’s capacity to reduce human anaerobic faecal flora was 
speculated to arise from the higher concentrations of the drug in the large intestine of the 
Crohn’s disease patients (Krook et al., 1981b). Taken together, it can be concluded that 
metronidazole may dose-dependently increase the number of aerobes in the colonic flora 
at the expense of the number of strict anaerobes.  
 
The physiological role and metabolic capacity of the intestinal flora 
 
The number of intestinal bacteria equals (Luckey, 1977) or exceeds (Cummings, 1983) 
the number of the cells in their human host. Because of the sparseness of the flora in the 
proximal GI tract, its metabolic activity is insignificant compared with those of the 
colonic flora. The accepted functions of the colon include the conservation of water and 
electrolytes and the controlled evacuation of faeces (Moran and Jackson, 1992). The 
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colon is, however, an important organ of its own with an influence on overall 
metabolism, and the effect may in large part be attributed to the activity of colonic 
microflora (Phillips, 1984). Its metabolic capacity has been estimated to be at least as 
great as that of the liver (Bingham, 1988) or even to exceed that of the rest of the human 
body (Luckey, 1977). Intestinal bacteria also have a short generation time and can 
undergo enzyme induction when exposed to high levels of substrate. This allows the 
microflora to adjust itself rapidly to any change in the environment (Gorbach and 
Goldin, 1990). 
 
One of the most important features is its protective function against pathogenic 
microbes. Antibiotic treatment may select resistant species or strains in the intestinal 
flora and lead to superinfections such as colitis caused by Clostridium difficile. 
Colonisation resistance by the normal intestinal flora is thus an important host defence 
mechanism. Bacteria are also the main source of antigenic materials and the intestinal 
flora is the most important stimulant of the body’s defence mechanisms (Gustafsson, 
1982). 
 
As stated earlier, the colonic microflora is predominantly anaerobic, and able to ferment 
carbohydrates. The main end-products of this bacterial fermentation are short-chain fatty 
acids (SCFAs). The carbohydrate available for fermentation in the colon comes from 
endogenous sources such as mucus, and exogenous dietary sources that escape digestion 
in the small intestine. The main SCFAs are acetate, butyrate and propionate, all of 
which have been shown to stimulate the growth and well-being of the colonic mucosa. 
Removal of fibre from the diet results in atrophy of the mucosa. This can be reversed by 
the infusion of SCFAs into the colon. Production of SCFAs lowers colonic pH and 
increases colonic motility. Moreover, since SCFAs stimulate colonic mucosal blood 
flow and oxygen uptake, there is evidence suggesting that bacterial fermentation is 
directly involved in colonic mucosal function and also more generally in mucosal 
metabolism (Cummings and Macfarlane, 1991). 
 
Bile acids are produced in the liver as end-products of cholesterol metabolism and 
excreted into the bile as conjugates. In the intestine the primary bile acids are attacked 
by microbial enzymes and transformed into a variety of metabolites, which may be 
absorbed and further transformed by liver enzymes prior to their re-excretion into the 
bile, forming the enterohepatic circulation of bile acids (Cummings, 1975). Intestinal 
microbes may also participate to a lesser extent in heme metabolism, the end product of 
which, bilirubin, is hydrolysed/deconjugated in the intestine by microbial and mucosal 
enzymes. The deconjugated bilirubin is reduced by microbial enzymes into a complex 
mixture of urobilinogens, which are excreted with the faeces. Some of these are also 
absorbed from the large intestine and reexcreted into the bile and urine (Gustafsson, 
1982). The intestinal microflora also metabolise sterols and steroid hormones. The 
steroid hormone metabolites reaching the intestine via the bile are usually conjugated 
with sulphuric acid or glucuronic acid. These conjugates are split by the intestinal 
microflora and the resulting free steroids are further degraded by the gut bacteria 
(Gustafsson, 1982).  
 
Bacterial enzymes play important roles in the metabolism of many drugs, often 
determining their bioavailability. For example, in 10% of patients given digoxin the 
drug is converted to inactive moieties by the gut flora (Lindenbaum et al., 1981). 
Bacterial metabolism may also be relevant to the biological effects of some drugs. An 
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example of this is a salicylazosulphapyridine, which is a complex drug containing an 
azo link between a sulphonamide and a salicylate. The two  moieties, linked by the azo 
bond which is resistant to mammalian enzymes, constitute a large molecule which is not 
absorbed in the small bowel. This allows the drug to reach the colon, where bacterial 
enzymes hydrolyse the azo bond, releasing sulphapyridine and salicylic acid. Since the 
components are thought to act therapeutically on the colon and then to be absorbed 
(Phillips, 1984), a symbiosis between colonic bacterial enzymes and a therapeutic effect 
is clear.   
 
The above examples show that the colonic flora has several physiological functions. 
Because any compound taken orally or entering the intestine via the biliary tract or 
blood stream is a potential substrate for bacterial transformation, bacterial flora with its 
enzymes is also very likely to be involved in many metabolic processes of foreign 
compounds and also exogenous and even endogenous ethanol (Goldin, 1990; Salaspuro, 
1996, 1997; Simon and Gorbach, 1984). 
 
Species differences in the intestinal flora 
 
Since conventional laboratory rats are widely used for studies on the metabolism of 
intestinal flora, in extrapolating the results obtained from the animal experiments to 
human subjects, it is important to know possible differences between the human and rat 
intestinal flora. The most notable differences lie in the upper regions of the gut. In man 
the stomach and duodenum normally harbour only transient flora, but these areas in rats 
are colonised by a mixed bacterial populations of about 107 - 108 organisms/g. The 
explanation for this is probably the bactericidal action of the strongly acidic gastric juice 
of the humans, whereas the pH of the rat stomach is more moderate (ph 4-5). The large 
intestine of rats is colonized by 103 to 10  5times higher concentrations of bacteria than 
the small intestine, and the colonic concentration of bacteria is equal to humans. Despite 
this, some differences have also been found in the activities of the reductive enzymes 
associated with the caecal and faecal floras of rats and humans. For example certain 
nitro compounds such as nitrobenzenes and dinitrotoluenes which depend on reduction 
by the gut flora for their toxic effects, can be much more potent in rats than in humans, 
who have much lower bacterial nitroreductase activity than the laboratory animals 
(Rowland, 1986). 
 
Taken together, large intestinal microflora in humans and rats are quantitatively 
comparable. Because much less is known about enzymatic similarities of the flora, 
caution must be taken in extrapolating results in this field. However, it may be possible 
to increase the degree of similarity in gut flora metabolism between laboratory rats and 
man by modifying the animal diet (Rumney and Rowland, 1992). 
 
 
2.3. DISTRIBUTION OF ETHANOL IN THE BODY 
 
Ethanol is absorbed by simple diffusion from the gastrointestinal tract because of its 
small size, good water solubility, and low solubility in lipids (Wallgren and Barry III, 
1970). No transport processes exist for ethanol (Crabb et al., 1987). Most of the ingested 
ethanol, 70-80%, is absorbed by the proximal small intestine, duodenum and upper 
jejunum. Slow diffusion from the stomach means that only about 20% of the oral dose is 
absorbed from the ventricle. After absorption, ethanol reaches the liver via the portal 
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vein (Riveros-Rosas et al., 1997). The rate of absorption is decreased by delayed gastric 
emptying (Oneta et al., 1998). Because gastric emptying is slow and prolonged with 
food in the stomach, drinking ethanol after eating a meal, regardless of the nutritional 
composition, delays its absorption. This produces a slower rise and lower peak value of 
the blood alcohol in fed than in fasting subjects (Jones et al., 1997). The concentration 
of the ingested ethanol also influences its absorption, at least when taken after a meal. It 
has been shown that postprandially taken high concentrations of ethanol result in lower 
blood alcohol levels than do dilute solutions, probably because of delayed gastric 
emptying  (Roine et al., 1991,1993; Roine 2000).  
 
Once ethanol reaches the blood, it is distributed rapidly throughout the body fluids. In 
organs with dense vascularization and rich blood supply, such as brain, lungs, and liver, 
alcohol rapidly equilibrates with the blood. In contrast, the distribution of alcohol to the 
resting skeletal muscle is particularly slow because of the low number of functioning 
capillaries (Agarwal and Goedde, 1990; Dundee et al., 1971). Poor lipid solubility 
allows tissue lipids to take up only 4% of the amount of alcohol that can be dissolved in 
a corresponding volume of water. Women, who have a smaller total water volume in the 
body than men, thus reach higher blood ethanol levels even if both sexes ingest identical 
quantities of ethanol (Riveros-Rosas et al., 1997). Distribution of alcohol is mainly 
related to the water content of various organs and tissues, so that, for instance, ethanol 
concentrations in the terminal ileum are approximately equal to those of the blood 
(Halsted et al., 1973). Their high water content makes the ethanol concentration in 
saliva (Jones, 1979) and urine (Bendtsen et al., 1999) slightly higher than that in the 
blood. 
 
Most of the ethanol (90-95%) is metabolised by oxidation and excreted as CO2 and 
water. Other routes for elimination are urine, sweat, and breath. Since alcohol is not 
concentrated in the urine or sweat, only negligible amounts of ethanol are excreted via 
urine (0.3%), and sweat (0.1%). In humans under normal conditions   0.7% can be 
eliminated through the lungs (Holford, 1987). 
 
 
2.4. HEPATIC ETHANOL AND ACETALDEHYDE METABOLISM 
 
It is generally agreed that the liver is the main organ responsible for the oxidation of 
ethanol. Estimations of the contribution of the liver to ethanol elimination under normal 
conditions vary from 75-90% (Agarwal and Goedde, 1990). However, in severe hepatic 
cirrhosis extrahepatic elimination of ethanol has been shown to account for up to 40% 
(Utne and Winkler, 1980). There are three metabolic systems capable of carrying out 
ethanol oxidation in the liver: cytosolic alcohol dehydrogenase, the microsomal ethanol 
oxidizing system located in microsomes, and catalase, located on peroxisomes. All these 
hepatic enzymes yield acetaldehyde as an end-product. Acetaldehyde is further 
converted to acetate, mainly in the mitochondria catalysed by aldehyde dehydrogenase.  
 
Alcohol dehydrogenase (ADH) 
 
ADH catalyses the reversible oxidation of many alcohols to corresponding aldehydes. In 
case of ethanol, the reaction is as follows: 
 
CH3CH2OH + NAD+  ⇔ CH3CHO + NADH + H+ 
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Alcohol dehydrogenase is abundant in the liver and its physiological role has been 
postulated to be the degradation of the low levels of alcohol produced by microbial 
fermentation in the gut. Another possible explanation is its role in the dehydrogenation 
of endogenous steroids (Krebs and Perkins, 1970).  
 
ADH is the main enzyme responsible for the oxidation of ingested ethanol in the liver. It 
is a dimer composed of approximately 40 kDa subunits and contains 2 zinc atoms per 
subunit. Six different classes of alcohol dehydrogenase have been described for 
mammalians; for humans, classes I-V and for rats, classes I-IV and class VI have been 
described (Jörnvall and Höög, 1995). In humans class I isoenzymes are coded by three 
genes (ADH1 to 3), and are explained by the presence of three protein subunits. In rats, 
class I ADH is encoded by one gene. Just recently a recommendation for a new 
nomenclature for expressing ADHs has been made. Five human ADH classes should be 
expressed by an Arabic number as follows: ADH1, ADH2, ADH3, ADH4, and ADH5. 
For genes, the italicized root symbol “ADH” for human and “Adh” for rat, followed by 
the appropriate Arabic number for the class; i.e. ADH1 or Adh1 for class I ADH genes 
has been recommended. Where multiple isoenzymes exist within a class, adding a 
capital letter after the Arabic number; i.e. ADH1A, ADH1B, and ADH1C for human  
class I ADHs was also suggested (Duester et al., 1999). In the literature the 
nomenclature has been confusing, and misconceptions about class distinction have 
frequently occurred. Since most papers have used the “older” nomenclature which codes 
classes with Roman numbers, this will be followed here. 
 
Class I ADHs, the classic liver alcohol dehydrogenases, are the most important enzymes 
in hepatic elimination of ethanol. These enzymes have a low Km (  1 mM) and high 
Vmax for ethanol, and are responsible for the bulk of ethanol oxidation. This means that 
ethanol is effectively eliminated from the blood at a constant rate to very low 
concentrations, provided that acetaldehyde is also effectively removed. As the Km of 
ADH for acetaldehyde is 0.6 mM it could act as a substrate in the reverse reaction (Blair 
and Vallee, 1966). However, the rapid transformation of acetaldehyde to acetate keeps 
the reaction in the forward direction. When alcohol is oxidized to acetaldehyde via 
ADH, nicotinamide adenine dinucleotide (NAD) is reduced to NADH. Normally the 
rate of NADH production exceeds its rate of reoxidation, resulting in an increase in the 
liver NADH/NAD ratio. This means that the redox state of the liver is markedly 
reduced. Most of the acute metabolic effects of ethanol, such as the inhibition of hepatic 
gluconeogenesis, the decrease in citric acid cycle activity and the impairment of fatty 
acid oxidation, arise from this major effect of ethanol on the intermediary metabolism of 
the liver (Lieber, 1994). 
 
The microsomal ethanol oxidizing system (MEOS) 
 
The first indication of a possible interaction between ethanol and the endoplasmic 
reticulum or microsomal fraction of the hepatocyte was provided by the observations 
that ethanol feeding results in a proliferation of the smooth endoplasmic reticulum 
(SER) in rats and human (Iseri et al., 1966; Lane and Lieber, 1966). This led Lieber and 
DeCarli (1968) to find the cytochrome P450-dependent system, which oxidizes ethanol 
to acetaldehyde as follows: 
 
CH3CH2OH + NADPH+ + H + O2  ⇒ CH3CHO + NADP+ + 2H2O 
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In humans, the cytochrome fraction responsible for ethanol oxidation has been 
designated as CYP2E1. This isoenzyme is the major contributor to the MEOS in 
humans, although later studies have suggested that other CYP forms may also play a 
role (Asai et al., 1996; Niemelä et al., 1999). The term MEOS should thus be 
maintained in referring to the overall capacity of the microsomes to oxidize ethanol 
rather than to that fraction of the activity specifically catalysed by 2E1 (Lieber, 1997). 
 
Since the Km of MEOS for ethanol is 7-10 mM, it contributes to ethanol elimination at 
high blood ethanol levels. This explains the fact that ethanol metabolism increases with 
rising ethanol concentrations above the level needed to fully saturate the low Km 
hepatic ADH (Lieber, 1997). The contribution of the MEOS to total ethanol elimination 
has not yet been fully clarified. Because of the slow turnover it may be limited, and it 
has been estimated that only a minor part (1-5%) of all ethanol metabolism in vivo is 
carried out by the MEOS (Ingelman-Sundberg, 1997). The most significant role of 
CYP2E1 is, however, its adaptive response to constantly high blood ethanol levels. This 
accounts for the metabolic adaptation to high concentrations of ethanol and the 
acceleration of ethanol metabolism resulting from chronic alcohol consumption. This 
metabolic adaptation has to be distinguished from the central nervous system adaptation 
to ethanol which results from chronic ethanol consumption, characterized by the 
progressive resistance of the brain to the effects of ethanol (Lieber, 1999). 
 
In addition to acetaldehyde production during ethanol oxidation, the MEOS has been 
shown to produce reactive oxygen intermediates, such as superoxide radicals. This may 
lead to enhanced lipid peroxidation, so that MEOS may contribute to alcoholic liver 
disease. Moreover, CYP2E1 has a capacity to activate over 80 toxicologically important 
xenobiotics to potentially hepatotoxic or carcinogenic products (Lieber, 1997). 
 
Catalase 
 
Catalase, which is located in peroxisomes, can oxidize ethanol to acetaldehyde when 
hydrogen peroxide is available as follows: 
 
CH3CH2OH + H2O2  ⇒ CH3CHO + 2H2O 
 
However, studies using the catalase inhibitor aminotriazole have shown that this 
compound does not slow ethanol metabolism in vivo (Teschke et al., 1976), and 
examination of the enzymatic reaction has suggested that the activity of catalase is 
limited in vivo by the bioavailability of hydrogen peroxide. Since the rate of hydrogen 
peroxide production in the liver is rather low (Boveris et al, 1972), there is some notion 
that catalase plays only a minor role in hepatic ethanol metabolism (less than 2%). 
 
Aldehyde dehydrogenase (ALDH) 
 
Regardless of the pathway by which ethanol is oxidised, acetaldehyde is the first 
metabolic product. Acetaldehyde is far more toxic than its parent compound ethanol. 
Fortunately, it is usually quickly further metabolised to acetate in the oxidative reaction 
catalysed by aldehyde dehydrogenase. The liver is the key organ for ethanol oxidation 
and the bulk of the ALDHs exist there. Human hepatic aldehyde dehydrogenase activity 
can be found in the mitochondria and cytosol (Agarwal, 1997). The main isoenzyme 
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responsible for the oxidation of acetaldehyde, both in humans and rats, has been shown 
to be the mitochondrial class 2 ALDH (ALDH2). This has a low Km (3 µM or less) and 
a high affinity for acetaldehyde (Lands, 1998). At high acetaldehyde concentrations, the 
increase in acetaldehyde oxidation is due to the activity of extramitochondrial ALDH, 
mainly cytosolic class 1 ALDH (ALDH1), which has a relatively high Km for 
acetaldehyde (100 µM) (Crabb et al., 1987). The low steady-state acetaldehyde 
concentration in the liver during alcohol metabolism (<10 µM) suggests that the 
mitochondrial isoenzyme is the main form responsible for the oxidation of acetaldehyde 
(Crabb et al., 1987). This is evidenced by experiments which show that NADH 
generated by the ALDH reaction appears almost exclusively in the mitochondria 
(Forsander, 1970).  
 
The central role of the low Km mitochondrial ALDH in acetaldehyde metabolism is 
strongly indicated by the finding that a mutation in the ALDH2 enzyme in humans 
results in impairment of the ability to dispose of acetaldehyde after ethanol ingestion. 
ALDH2 isoenzyme has two allelic forms; the active ALDH2*1 and the relatively 
inactive ALDH2*2. Patients homozygous for the ALDH2*2 allele lack ALDH2 activity, 
while patients heterozygous for this allele exhibit approximately half the activity of 
ALDH2*1 homozygotes (Crabb et al., 1989). Deficient ALDH2 isoenzyme has been 
found in about 50% of Japanese (Goedde et al., 1979). The homozygous form of 
inactive ALDH2 offers full protection against alcoholism. This has been proposed to be 
due to the accumulation of acetaldehyde in the blood during alcohol metabolism, which 
causes aversive sensations (Peng et al., 1999). Heterozygotic subjects with about half 
the normal ALDH2 activity can, however, drink alcohol or develop even alcohol 
dependency (Wall et al., 1992). After ethanol intake the heterozygotic subjects show 
flushing, palpitations and nausea, which are caused by elevated blood acetaldehyde 
levels (Wall et al., 1992). Blood acetaldehyde levels in heterozygotic subjects have been 
shown to be between 8 and 24 µM even after a very low dose (0.1 g/kg of body weight) 
of ethanol (Enomoto et al., 1991). In contrast, normal healthy subjects have very low 
levels (< 0.5 µM) of acetaldehyde in the peripheral blood during ethanol oxidation 
(Eriksson and Fukunaga, 1993). This indicates that in normal healthy individuals almost 
all the acetaldehyde formed is effectively oxidised in the liver. Heavy drinkers with the 
heterozygous ALDH2*2 genotype (ALDH2*1/2*2) can be considered as human 
“knock-out models” for deficient acetaldehyde removal. Consequently, the toxicity of 
acetaldehyde is strongly corroborated by the fact that individuals with the heterozygous 
ALDH2*2 genotype are at higher risk of developing alcohol abuse-related GI-tract 
cancer as compared to those with the normal ALDH2 genotype (Yokoyama et al., 1998). 
 
The end-product of hepatic ethanol oxidation, acetate, leaves the liver via hepatic 
venous blood, and is almost completely converted to CO2 and H2O in the peripheral 
tissues, mainly in the muscles. 
 
 
2.5. METABOLISM OF ETHANOL AND ACETALDEHYDE IN THE 
DIGESTIVE TRACT 
 
Ethanol metabolism 
 
Although the liver is the major organ responsible for ethanol metabolism, such 
metabolism also occurs in the digestive tract. Intestinal metabolism of ethanol is of 
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considerable importance, since it may affect the systemic availability of alcohol and lead 
to local production of acetaldehyde, possibly resulting in tissue injury. 
Immunohistochemical studies have revealed that alcohol dehydrogenase can be detected 
in the mucosa of all parts of the gastrointestinal tract. Furthermore, the amount of ADH 
observed was higher in epithelial cells exposed to the lumen than in cells at the bottom 
of crypts (Pestalozzi et al., 1983). In addition to their localization, the contribution of 
the various ADH isoenzymes to ethanol metabolism depends on their kinetic 
parameters, particularly their Km values.  
 
Class IV ADH is characteristic of the upper GI tract, including the mouth and the 
esophagus (Dong et al., 1996; Yin et al., 1993). The Km values of the gingival ADH 
was estimated to be 27 mM (Dong et al., 1996), and of esophageal class IV 12 mM (Yin 
et al., 1993) These high Km values suggest that ethanol may be significantly 
metabolised in these tissues. Moreover, the esophagus is the organ of highest ADH 
activity in the GI tract, with a rate per mg of protein similar to that of the liver and 
approximately 4 times that of the stomach enzyme (Parés and Farrés, 1996).  
 
ADH was detected in human gastric mucosa decades ago (Hempel and Pietruszko, 
1979; Smith et al., 1972) and has been shown to exhibit multiple isoenzymes. Class IV 
ADH and class I ADH coexist in the stomach, with Km values of 40 and approximately 
1 mM respectively (Parés et al., 1992; Seitz and Oneta, 1998; Yin et al., 1997). Since 
the stomach contains both high Km class IV ADH and low Km class I ADH, this organ 
is a transition site for switching expression of class IV ADH to class I ADH, which is 
predominant in the rest of the intestinal tract (Yin et al., 1997). The significance of 
gastric ADH is its suggested role in the first pass metabolism of ethanol (FPM). The 
gastric FPM of ethanol has been used to explain the differences in the areas under the 
ethanol concentration-time curves (AUC) obtained after oral and intravenous alcohol 
application. However, the relative contribution of gastric and hepatic metabolism to 
FPM is still a subject of debate. Some studies suggest that the differences in AUCs may 
be due to the differences in ethanol absorption, and therefore speculate that gastric 
ethanol metabolism in rats is negligible and that there is no evidence for this 
phenomenon in humans (Smith et al., 1992). By contrast, there are studies indicating a 
significant role for gastric ethanol metabolism in the FPM (Caballeria et al., 1987; Lim 
et al., 1993). The estimations of FPM of ethanol to ethanol metabolism range between 
1% and 20% (Seitz and Pöschl, 1997).  
  
The small and large intestinal ADH is mainly composed of class I ADH, with a Km of 
1-2 mM for ethanol (Seitz and Oneta, 1998). The activity of rectal ADH was 
comparable to gastric ADH activity and, compared to ADH activities in other colonic 
segments, was found to be significantly higher (Seitz et al., 1996). This suggests that 
ethanol may be effectively metabolised to acetaldehyde in the colonic mucosa and 
especially in the rectal mucosa.   
 
In addition to ADH, rat gastric mucosa have been shown to possess catalase activity 
(Salmela et al., 1996), but its presence in the rest of the alimentary tract is unknown. 
Moreover, immunohistochemistry has revealed that rat duodenal and jejunal villous 
cells exhibit CYP2E1 activity, but it is not expressed or induced in the stomach, ileum, 
colon and rectum (Shimizu et al., 1990). 
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Acetaldehyde metabolism 
 
Cytosolic high Km ALDH3 is the only ALDH isoenzyme identified in the human mouth 
thus far. Both gingival and tongue tissue ALDH exhibit significant amounts of enzyme 
activity at 20 mM acetaldehyde (Dong et al., 1996). Regarding human gastric mucosa, 
ALDH3 has been estimated to account for more than 80% of the ALDH activity. 
Although ALDH3 has a high Km value for acetaldehyde (approximately 88 mM), it has 
been suggested that acetaldehyde generated by gastric ADH could be oxidized in the 
same tissue (Parés and Farrés, 1996; Yin et al., 1997). A different picture is seen in the 
esophagus, where the ALDH3 activity is 5 times below that of the gastric mucosa, while 
the rate of acetaldehyde production is higher than in the stomach (Yin et al., 1993). 
Accumulation of acetaldehyde could thus occur in esophageal tissue, contributing to the 
alcohol-related end-organ damage. ALDHs classes 1 and 2 can be found in the human 
duodenum (Liao et al., 1991), but much less is known about the ALDH activity of the 
rest of the small intestine. ALDHs 1, 2, and 3 have been observed in human and rat 
colonic mucosa, but the expression of low-Km mitochondrial ALDH2 seems to be 
particularly low (Koivisto and Salaspuro, 1996; Yin et al., 1994). The activity ALDH in 
the colonic mucosa was only slightly lower in ALDH2-deficient subjects than in normal 
phenotype carriers, suggesting that mucosal ALDH2 plays only a minor role in the 
oxidation of acetaldehyde in the colon (Yin et al., 1994). 
 
 
2.6. MICROBIAL ETHANOL FERMENTATION AND OXIDATION 
 
Endogenous ethanol 
 
Measurable amounts of ethanol are normally formed in the gastrointestinal tract. In the 
caecum of normally fed rats, the mean ethanol concentration has been shown to be 0.9 
mM. This endogenous alcohol, which derives from anaerobic degradation of glucose to 
ethanol by some microorganisms, is absorbed into the portal circulation and almost 
quantitatively removed by the liver (Krebs and Perkins, 1970). Conditions associated 
with bacterial overgrowth producing markedly elevated endogenous ethanol levels 
detected even in the blood indicate intestinal microbial-derived ethanol production in 
humans. For example, in some patients after a jejunoileal bypass operation, detectable 
fasting serum concentrations of ethanol up to 1 mM have been noted. In the past this 
kind of operation resulted in blind-loop formation and consequent colonisation and 
bacterial overgrowth of that segment (Mezey et al., 1975). Additionally, midjejunal 
aspirates from the patients with tropical sprue show not only an overgrowth of 
coliformic bacteria (Klebsiella pneumoniae, Enterobacter cloacae and Escherichia coli) 
but also large quantities of their fermentation end-product ethanol with concentrations 
from 2 mM to 31 mM (Klipstein et al., 1973). Small amounts of endogenous ethanol (1 
to 27 mM) have also been found in the gastric juice of patients receiving cimetidine or 
antacids. Bode et al. (1984a) speculated that this resulted from an increase in the yeast 
and/or bacterial population in the stomach due to the reduction of gastric acid induced 
by the medication.  
 
The last step in bacterial alcoholic fermentation is the reduction of acetaldehyde to 
ethanol, catalysed by bacterial ADH (Reid and Fewson, 1994; Tamm, 1974). This has 
been described in full detail in the case of Escherichia coli (Clark, 1989; Dawes and 
Foster, 1956; Still, 1940; Wong and Barrett, 1983), group N Streptococci (Lees and 
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Jago, 1976) as well as within the Enterobacteriaceae in general (Salveson and Bergan, 
1981). As already stated, this reaction is also reversible in microorganisms (Maconi et 
al., 1988). This means that if oxygen is present and given an excess of ethanol, the ADH 
mediated reaction can also run in the opposite direction and ethanol may be oxidized to 
acetaldehyde in a reaction in which nicotinamide adenine dinucleotide acts as an 
electron acceptor. 
 
Microbial acetaldehyde production in vitro 
 
As mentioned earlier, E. coli was shown to possess ADH activity in 1940 by Still. 
Jokelainen et al. (1996a) showed that different strains of faecal E. coli and other Gram-
negative rods, mainly belonging to the Enterobacteriaceae family, were able to produce 
significant amounts of acetaldehyde when incubated aerobically in vitro with ethanol in 
reaction catalysed by NAD-dependent ADH. Later studies have shown that E. coli is 
also able to oxidize ethanol in microaerobic conditions, i.e. when 6% O2 is present 
(Salaspuro et al., 1999). This is important, since the PO2 in the colonic mucosa is 
known to be approximately equal to that of venous blood, and hence the conditions in 
the colon are more or less microaerobic (Hamilton et al., 1968). It was shown earlier 
that human colonic contents, i.e. the mixture of colonic bacteria, can produce 
acetaldehyde from ethanol in a dose-dependent manner in vitro (Jokelainen et al., 1994). 
The significant acetaldehyde production occurred at the ethanol concentrations that are 
relevant to in vivo conditions. These findings have opened up a new microbiological 
approach to researching acetaldehyde production and its pathological consequences in 
the gastrointestinal tract.   
 
Regarding the upper digestive tract, in vitro production of acetaldehyde has been 
reported when human mouth- and bronchopulmonary washings were incubated 
aerobically with ethanol. Since acetaldehyde production could be abolished by 
pretreatment with antibiotics, acetaldehyde formation from ethanol was thought to be of 
bacterial origin (Jauhonen et al., 1982; Miyakawa et al., 1986; Pikkarainen et al., 1981). 
Interestingly, in vitro acetaldehyde production by mouthwashings from oropharyngeal 
cancer patients has been shown to be significantly higher than that of the control 
patients (Jokelainen et al., 1996b). This suggested that microbially derived acetaldehyde 
production could be involved in ethanol-associated organ toxicity. 
 
Helicobacter pylori also exhibits significant cytosolic ADH activity. Consequently, H. 
pylori has been shown to produce acetaldehyde when intact cells are incubated with 
ethanol, and this has been speculated to contribute to H. pylori-associated 
gastroduodenal injury (Roine et al., 1992, 1995; Salmela et al., 1993, 1994).  
 
Microbial acetaldehyde production in vivo 
 
Regarding the human oral cavity, the production of marked amounts of acetaldehyde up 
to 140 µM in saliva after the ingestion of a moderate amount of ethanol has been 
demonstrated. This acetaldehyde production was significantly reduced by the use of 
antiseptic chlorhexidine mouthwash, indicating its microbial origin (Homann et al., 
1997a). Another important finding in the same study was that in vivo salivary 
acetaldehyde levels correlated highly significantly with the acetaldehyde levels produced 
in vitro. This offers an opportunity to use the in vitro salivary test to reliably 
differentiate high acetaldehyde producers from low producers.  
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Intestinal in vivo microbially derived ethanol oxidation and acetaldehyde production 
have been shown to occur in rats with a jejunal self-filling diverticulum and 
concomitant bacterial overgrowth (Baraona et al., 1986). Moreover, after an acute dose 
of ethanol to rats, the rectal mucosal acetaldehyde concentration was significantly higher 
in conventional rats than germ-free rats, indicating the role of microbes in acetaldehyde 
production (Seitz et al., 1990). Ethanol oxidation to acetaldehyde has also been detected 
in the caecum of anaesthetized pigs after intragastric or intravenous ethanol 
administration (Jokelainen et al., 1996c). Furthermore, high intracolonic acetaldehyde 
levels have been detected in the caecal samples of rats after intraperitoneal ethanol 
administration, and these levels were effectively suppressed by pre-treatment with 
ciprofloxacin, which reduces the amount of aerobic bacteria in the large intestine 
(Visapää et al., 1998). These findings strongly suggest that microbes of the large 
intestine are able to oxidize ethanol by a bacteriocolonic pathway for ethanol oxidation. 
 
In a very recent human study, we also showed ethanol-derived acetaldehyde production 
in the stomach after treatment with lansoprazole. Medication led to marked bacterial 
overgrowth in the neutral stomach, and this was considered to be the most probable 
explanation for the enhanced acetaldehyde production detected (Väkeväinen et al., 
2000).  
 
Microbial acetaldehyde metabolism 
 
Aldehyde dehydrogenase activity has been identified in the cytosol of yeasts (Steinman 
and Jakoby, 1968) and in anaerobic bacteria (Burdette and Zeikus, 1994). ALDH 
activity also exists in facultative anaerobic bacteria, which are able to produce 
acetaldehyde via ADH. Escherichia coli has been shown to exhibit aldehyde 
dehydrogenase activity (Dawes and Foster, 1956; Wong and Barrett, 1983). Nosova et 
al. (1996) studied 27 different bacterial species, mainly belonging to the family 
Enterobacteriaceae, and showed them to be capable of cytosolic NAD or NADP-linked 
ALDH activity. However, based on kinetic studies, the ability of bacterial ALDHs to 
oxidise higher concentrations of acetaldehyde was rather low (Nosova et al., 1998). 
Taken together with low ALDH activity in the colonic mucosa (Koivisto and Salaspuro, 
1996), this offers an additional explanation for the mechanism of the accumulation of 
ethanol-derived acetaldehyde in the large intestine.  
 
 
2.7. ALCOHOL AND THE ALIMENTARY TRACT 
 
Symptoms and functional changes associated with alcohol use. 
 
Excessive alcohol consumption is frequently associated with gastrointestinal symptoms. 
Although most symptoms after both acute and chronic use of alcohol are reversible and 
disappear during abstinence, chronic use of alcohol may cause structural or functional 
changes that can lead to permanent gastrointestinal diseases. An example of this is the 
increased risk of colorectal adenomatous polyps, which are generally regarded as 
premalignant lesions (Cope et al., 1991). Alcohol consumption and the risk of colorectal 
cancer will be discussed in the next chapter. 
 
Only the upper digestive tract, mouth, esophagus, stomach and upper small intestine are 
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directly affected by the ingested ethanol. However, since ethanol is transported by blood 
circulation to other organs ethanol concentrations in the terminal ileum (Halsted et al., 
1973) and colon (Levitt et al., 1982) are approximately equal to those of the blood. A 
questionnaire showed that actively drinking alcoholics more frequently report heartburn, 
nausea, vomiting, diarrhea, and flatulence than the matched controls. These symptoms 
were transient and resolved after two weeks of sobriety. An important note of the study 
was that these symptoms were associated with active alcohol use and were not 
withdrawal symptoms (Fields et al., 1994). 
 
The etiology for the increased incidence of GI symptoms in alcoholics is probably 
multifactorial. Moreover, prolonged use of alcohol may have effects which differ from 
the acute effects of a single dose. Some studies suggest that acute alcohol ingestion may 
impair the function of the lower esophageal spinchter and reduce the incidence of 
primary peristalsis in the distal esophagus (Hogan et al., 1972; Mayer et al., 1978), 
although some others have reported the reverse (Keshavarzian et al., 1987; Silver et al., 
1986). However, there is evidence that acute alcohol intake increases esophageal reflux 
episodes and impaires the acid clearance of the esophagus in the supine position 
(Kaufman and Kaye, 1978; Vitale et al., 1987). This may explain the increased 
incidence of heartburn in heavy alcohol users. 
 
Acute ingestion of alcohol has been shown to produce inflammatory changes in the 
stomach and duodenum of humans. The most prominent findings included 
haemorrhagic erosions, subepithelial blebs and infiltration of inflammatory cells into the 
lamina propria (Gottfried at al., 1978). Rubin et al. (1972) showed that after sustained 
use of ethanol, the histology of the human small intestine was normal when examined 
by normal light microscopy, but morphometric and electron microscopic examinations 
demonstrated alterations in the cell organelles of the mucosa. Others have, however, 
shown reduction in the villus height and a reduced mucosal surface area of villi in the 
small intestine of actively-drinking alcoholics (Bode et al., 1982a; Persson, 1991; Seitz 
et al., 1985). Several enzymes known to be located in the absorptive cells may also be 
affected by ethanol. Reduced activity in disaccharidases has been noted after sustained 
high ethanol administration (Bode et al., 1982b). Decreased lactase activity can 
contribute to milk intolerance with diarrhea commonly observed in alcoholics after a 
period of heavy drinking (Keshavarzian et al., 1986; Persson, 1991). Moreover, oral-
caecal time has been shown to be decreased in recently drinking alcoholics, suggesting 
that the increasing transit of intestinal contents may contribute to the diarrhea commonly 
seen during and after an episode of heavy drinking (Keshavarzian et al., 1986). Chronic 
alcohol use has also been shown to induce both histological and ultrastructural changes 
in the human rectal mucosa. These reversible changes include inflammatory changes, a 
decreased number of goblet cells, and alterations in the cell organelles (Brozinsky et al., 
1978).   
 
The nutritional status of advanced alcoholics is often poor, at least among lower-income 
and homeless alcoholic populations. The etiology of malnutrition has been generally 
thought to be multifactorial (Salaspuro, 1993). On average, ethanol accounts for about a 
half of an alcoholic’s caloric intake. It therefore displaces normal nutrients, causing 
malnutrition (Lieber, 1995). Secondary malnutrition also occurs through malabsorption 
due to the structural and functional changes in the small intestine, but pancreatic 
exocrine insufficiency, decreased biliary secretion and impaired hepatic metabolism of 
nutrients may also be involved (Lieber, 1995; Salaspuro, 1993).  
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Both acute and chronic exposure to ethanol has been shown to increase intestinal 
permeability to macromolecules in experimental animals. Increased small intestinal 
permeability has also been observed in human alcoholic patients without liver cirrhosis. 
This “leaky gut” phenomenon was shown to persist up to 2 weeks after cessation of 
drinking (Bjarnason et al., 1984), and seems to result from a temporary destabilization 
of intracellular junctions (Draper et al., 1983). Interestingly, high acetaldehyde levels 
have been shown to reversibly increase the paracellular permeability of the Caco-2 cell 
monolayer (Rao, 1998). Acetaldehyde production by the intestinal bacteria may thus be 
one mechanism by which prolonged alcohol use increases intestinal permeability. The 
disruption of the mucosal barrier may promote absorption of normally nonabsorbable 
compounds like endotoxins into the portal circulation (Bjarnason et al, 1984; Persson, 
1991). Moreover, leaky gut has recently been suggested as a possible mechanism for 
alcohol-induced liver damage (Keshavarzian et al., 1999). 
 
Alterations in the oral and intestinal flora caused by chronic alcohol intake 
 
There are no studies available to show whether heavy alcohol consumption directly 
alters the oral flora. However, although the overall dental health in subjects misusing 
alcohol, investigated by the decayed, missing and filled teeth (DMFT) index, has been 
shown to be only slightly poorer than national averages in the United Kingdom, a high 
incidence of tooth wear and trauma to the dentition was noticed (Harris et al., 1996, 
1997). Tooth wear was presumed to be caused by the regurgitation of gastric acid. This 
study suggests that the dental hygiene habits of alcohol misusers may be poorer than that 
of abstainers or moderate drinkers. Poor dental hygiene habits may favour the 
overgrowth of some microbes in the oral flora. Moreover, poor dietary factors and the 
suppressive effects of alcohol intake on various arms of the host immune defence may 
predispose to colonization by some bacteria and yeasts in the oral cavity (MacGregor, 
1986; Oksala, 1990). Additionally, most heavy alcohol drinkers are also heavy cigarette 
smokers (Harris et al., 1996). Heavy smoking may be the strongest factor predisposing 
to microbial colonisation in the oral cavity since it has been shown to increase the 
presence of yeasts and Gram-positive aerobic bacteria there (Colman et al., 1976; 
Macgregor 1988; Rindum et al., 1994; Sakki and Knuuttila, 1996). Moreover, heavy 
alcohol consumption in humans has been associated with a marked (70%) reversible 
reduction in the flow rate of stimulated parotid saliva. Beside this, chronic alcohol abuse 
also reduces protein secretion, like amylase and epidermal growth factor (EGF), in 
parotid saliva (Dutta et al., 1992). Ohmura and coworkers (1987) suggested that low 
EGF levels in saliva may decrease the resistance of the mucosal barrier to chemical 
stress. Therefore, low salivary levels of EGF may be one possible mechanism by which 
ethanol or acetaldehyde may influence the development of oral lesions associated with 
alcohol use.   
 
Marked qualitative and quantitative changes have been observed in the flora of the small 
intestine of chronic alcoholics. The most significant finding was the increase in the 
number of bacteria per unit volume of jejunal juice, especially in the number of aerobic 
and facultative anaerobic Gram-negative rods and obligate anaerobic bacteria (Bode et 
al., 1984b). Evidence for an increased incidence of bacterial overgrowth in alcoholics 
also stems from studies using the hydrogen breath test after ingestion of lactulose (Bode 
et al., 1989). Mucosal bacterial overgrowth has also been detected more often and with 
higher microbial counts in the biopsy samples of the stomach and duodenum among 
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alcoholics (Hauge et al., 1997). This upper GI tract bacterial overgrowth has been 
speculated to be due to the increased pH of the gastric juice.  
 
Small intestinal bacterial overgrowth may lead to malabsorption or morphological 
changes in the small intestinal mucosa (Persson, 1991). Moreover, bacterial overgrowth 
might contribute to the increased release of endotoxin and lead to endotoxemia, which is 
often detected in patients with alcoholic liver disease (Bode, 1987). Endotoxin, a cell-
wall constituent of Gram-negative bacteria, may play a role in alcoholic liver injury by 
activating macrophages to release cytokines (McClain et al., 1999). The small intestinal 
bacterial overgrowth may thus also contribute to the pathogenesis of extraintestinal 
disorders associated with alcohol use. Bacterial overgrowth probably also leads to 
increased microbially-derived acetaldehyde production from ethanol in the small 
intestine. 
 
 
2.8. ALCOHOL AND DIGESTIVE TRACT CANCERS 
 
Cancer of the oropharynx and esophagus 
 
There is extensive epidemiological evidence, mainly from case-control studies although 
also from cohort studies, showing that tobacco smoking and heavy alcohol consumption 
increase the risk of cancers of the mouth, pharynx, esophagus and larynx (Doll et al., 
1999; Franceschi et al., 1990; Grønbæk et al., 1998; Mashberg et al., 1993; Merletti et 
al., 1989). In Europe these factors have been estimated to account for about three-
quarters of all cases (La Vecchia et al., 1997). Both smoking and alcohol consumption 
have been shown to be independent risk factors for upper digestive tract cancers. The 
cancer risk increases proportionally with the quantity of cigarettes smoked or alcoholic 
beverages drunk. When combined, there is epidemiological evidence indicating that 
alcohol and tobacco act together in a multiplicative rather than in an additive manner, 
having synergistic tumour-promoting effects (Blot et al., 1988; Brugere et al., 1986; La 
Vecchia et al., 1997). This means that the combined effect of both of these agents is 
greater than simply adding the effects of each together. Many attempts have been made 
to separate the effects of different types of alcoholic beverages in their potential for 
carcinogenicity. The consensus, however, is that the main component of alcoholic 
beverages determining the risk of cancer is ethanol (Doll et al., 1999). This is further 
supported by the fact that the regular use of mouthwashes with a high ethanol content 
increases the risk of oropharyngeal cancer (Winn et al., 1991). 
 
Other possible risk factors for upper gastrointestinal tract cancer are poor nutritional 
status and intake of micronutrients, hereditary factors, certain papilloma viruses, and 
occupational hazards (Bundgaard et al., 1995; Graham et al., 1977; La Vecchia et al., 
1997; Marshall et al., 1992; Marshall and Boyle, 1996). Moreover, dentition, tooth loss, 
poor dental status and oral hygiene habits are associated with higher risks, especially for 
oral cavity cancer (Bundgaard et al., 1995; Graham et al., 1977; Maier et al., 1993; 
Marshall et al., 1992). It is generally agreed that the influence of poor oral hygiene as a 
risk factor is much less compelling than alcohol and smoking, but there is some 
experimental evidence that its influence might become clinically more important among 
alcoholics, whose poor dental status and hygiene may be a common problem (Maier et 
al.,1993). The reason for this finding is unclear.  
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Although alcohol and tobacco smoke are well-known independent and strong risk 
factors for upper gastrointestinal tract cancer, the exact mechanism by which they exert 
an influence upon the oral mucosa is poorly understood. Consequently, the only things 
known to reduce the risk of upper digestive tract cancers is to limit alcohol consumption 
and to stop or never start using tobacco and, perhaps, to have a regular diet rich in fruit 
and green vegetables (Harris, 1997). Many compounds in tobacco smoke are hazardous 
to health and some are undoubtedly carcinogenic (IARC, 1986). In contrast, the tumour-
promoting effects of alcohol consumption are less well defined. Moreover, ethanol is 
not a carcinogen by standard laboratory tests. As alcohol is involved synergistically in 
the attributable risk of cigarette smoking, it has been suggested that unifying 
pathogenetic mechanism may underlie these epidemiological findings. The possible 
mechanisms by which alcohol may influence the development of cancers are discussed 
separately, with special reference to acetaldehyde in chapter 2.9. 
 
Cancer of the stomach 
  
Most epidemiological retrospective cohort studies show no increase in the stomach 
cancer rate among alcoholics or heavy drinkers. In these studies cancer incidence in 
groups with high alcohol intake was compared with that of the general population. In 
follow-up studies of populations with known consumption most studies showed no 
elevated risk, with RR from 0.9 to 1.2 (Doll et al., 1999). However, two studies (Gordon 
and Kannel, 1984; Kato et al., 1992) reported a significant increase with heavy drinking, 
with a relative risk of 3.05 in the study by Kato et al. In that study stomach cancer 
mortality was prospectively studied among 9753 Japanese, who frequently show the 
presence of partially inactive ALDH 2*2 isoenzyme (Goedde et al., 1979). It has since 
been shown that the mutant allele is associated with higher frequency of GI 
malignancies, including stomach cancer, if alcohol is consumed regularly (Yokoyama et 
al., 1998). This limits the extrapolation of this study to Caucasians with no such enzyme 
defect, but indicates the role of acetaldehyde in carcinogenesis associated with alcohol 
use. Some case-control studies have shown a significant positive relationship between 
alcohol consumption and stomach cancer (RR 1.5 - 1.7), whereas others showed no 
significant relationship (Doll et al., 1999). Taken together, epidemiological evidence 
between alcohol consumption and cancer of the stomach is far from clear. Moreover, 
there has been a dramatic worldwide decline in the incidence of stomach cancer, a 
finding in contrast to the general increase in alcohol consumption and alcohol-related 
diseases such as cirrhosis of the liver. IARC stated in 1988 that there is little aggregate 
data to suggest a causal link between drinking alcoholic beverages and stomach cancer. 
However, Doll et al. (1999) later concluded that alcohol may have an etiological role in 
the stomach cancer, albeit minor and unproven. 
 
An exception to this may be the cancer of the gastric cardia, the incidence rates of which 
have been recently increasing. The cardia region of the stomach is the uppermost area 
where the stomach adjoins the esophagus. It has been suggested that this cancer 
resembles a specific type of cancer of the lower oesophagus and may share common risk 
factors, notably tobacco and alcohol exposure (Vaughan et al., 1995). 
 
Cancer of the large intestine 
 
As with gastric cancer, there is considerable epidemiological data concerning the 
possible association between cancer of the large bowel and consumption of alcoholic 
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beverages. Some studies showed no evidence of such an association, while others 
showed a statistically significant association. The rest of the studies were somewhere 
“in-between” showing no consistent and significant overall association, but the RRs 
were elevated in some subgroups (Doll et al., 1999). However, two different meta-
analyses of more than 60 studies between 1951 and 1991 both conclude that alcohol 
leads to a small but significantly increased cancer risk, especially for the left colon and 
the rectum with an estimated overall RR of 1.1 (95% CI 1.05-1.14) (Kune and Vitetta, 
1992; Longnecker et al., 1990). Moreover, just recently a panel of European experts at a 
World Health Organization (WHO) Consensus Conference on Nutrition and Colorectal 
Cancer declare that alcohol had a causal effect in colorectal carcinogenesis (Scheppach 
et al., 1999). 
 
Possible mechanisms of ethanol-induced carcinogenesis 
 
It has been concluded that there is sufficient evidence for the carcinogenicity of 
alcoholic beverages in humans (IARC, 1988), but there is no experimental evidence to 
indicate that ethanol itself is a carcinogen (Doll et al., 1999). This means that pure 
ethanol has not been shown to be carcinogenic in laboratory experiments. In in vitro 
studies with human and other mammalian cells it has been shown that ethanol does not 
induce DNA damage, sister chromatid exchanges or chromosomal aberration. Most of 
the in vivo studies with mice or rats described in the literature cannot be used to evaluate 
the carcinogenicity of alcohol due to limitations in experimental design (IARC, 1988). 
 
Animal experiments suggest, however, that ethanol may act as a co-carcinogen in the 
production of cancers. This means that it modifies or enhances the carcinogenic 
potential of known carcinogens. Grici t  et al. (1982, 1984) exposed C57B mice by 
gastric intubation to N-nitrosodiethylamine (NDEA) or N-nitrodi-n-propylamine 
(NDPA), either in tap water or in a 40% ethanol solution, twice a week for 50 weeks. A 
significant increase in the incidence of squamous cell carcinomas of the 
esophagus/forestomach was observed in the group given the carcinogens in ethanol as 
compared to those given the nitrosamines in the tap water. Seitz et al. (1984) studied the 
effect of chronic ethanol administration on 1,2-dimethylhydrazine (DMH) induced rectal 
carcinogenesis in male rats fed a nutritionally adequate liquid diet containing 36% of 
total energy as ethanol or isocaloric carbohydrate. Sustained ethanol ingestion increased 
the number of rectal tumours significantly (17 vs. 6; p<0.02).  
 
Although many hypotheses exist, experimental work has so far failed to elucidate the 
underlying mechanisms by which excessive consumption of alcoholic beverages may 
act as a co-carcinogen under certain conditions. Some of these hypotheses are listed 
below. 
 
Alcohol may contain congeners and other contaminants that may be carcinogenic. 
Several substances known or thought to cause cancer in humans have been detected in 
alcoholic beverages. Special attention has been paid to N-nitroso compounds, which 
have been related to colorectal cancer in humans (Knekt et al., 1999). Several N-nitroso 
compounds, e.g. nitrosodimethylamine (NDMA), have been found in higher 
concentrations in some beers than in other beverages (Walker et al., 1979). This is a 
possible mechanism for a specific carcinogenic effect of beer drinking in relation to 
rectal cancer. While some studies have found an elevated risk (Riboli et al., 1991), these 
were not confirmed by others (Potter and McMichael, 1986). The consensus is that there 
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is no appreciable and consistent difference in the risk among different types of alcoholic 
beverages (Doll et al., 1999).  
 
Alcohol intake generates metabolites which may be carcinogenic to humans, or ethanol 
itself may act as a solvent, increasing penetration of other carcinogens into the target 
tissue (Wight and Ogden, 1998). The major metabolite of ethanol is acetaldehyde. There 
is sufficient evidence for the carcinogenicity of acetaldehyde to experimental animals 
(IARC 1985, 1999), and indirect strong epidemiological evidence in humans 
(Yokoyama et al., 1998). Because of the central role of acetaldehyde in the studies of 
this thesis, this topic will be discussed separately in the next chapter. 
 
Either alcohol intake may reduce the intake and/or bioavailability of nutrients which 
could inhibit cancer, or alcohol consumption may enhance nutritional deficiencies that 
increase the risk of cancer. In some cases, nutritional deprivation may lead to nutritional 
deficiencies that may alter epithelial cell chemistry and function, increasing 
susceptibility to carcinogens (Blot, 1992), an example being folate deficiency. In 
epidemiological studies, decreased folate status has been associated with an increased 
risk of neoplastic transformation in the colon (Giovannucci et al., 1995). The 
pathogenetic mechanism of the increased cancer risk in folate deficiency has been partly 
elucidated. Folate is a crucial methyl group donor for many transmethylation reactions 
in the human body. Diminished folate leads to hypomethylation of the DNA, which has 
been observed in several experimental cancer models and in human cancers (Goelz et 
al., 1985; Kim et al., 1997). Since high levels of acetaldehyde have been shown to be 
able to catabolize folate in vitro (Shaw et al., 1989), there is conjecture that alcohol 
intake and low folate together could play a role in colorectal carcinogenesis 
(Anonymous, 1994; Boutron-Ruault et al., 1996; Collins et al., 1992; Giovannucci et al., 
1995). 
 
Prolonged alcohol use may also inhibit the detoxification of carcinogenic compounds. 
Experimental studies have suggested that the effects of alcohol on the liver may block 
hepatic inactivation of carcinogens, thus increasing exposure to these compounds (Blot, 
1992). Moreover, heavy alcohol use may catalyse the metabolic activation of some 
compounds into carcinogens. For example, alcohol intake induces hepatic CYP2E1, 
which also has a unique capacity to activate over 80 toxicologically important 
xenobiotics to potentially carcinogenic products (Lieber, 1997). Since oxygen free 
radicals are generated during alcohol metabolism, target cells may be exposed to 
oxidants and this may lead to activation of carcinogens at the cellular level. Increased 
oxidative stress may also increase the risk of DNA damage and malignant 
transformation. However, the tumour promotion associated with alcohol and with the 
generation of free radicals is in general not very clear and the role played by ethanol in 
this process is even less so (Mufti et al., 1993).  
 
Alcohol is also known to cause immunosuppression, a possible contributing factor in 
the increased cancer rate among alcoholics. The role of immunosuppression in ethanol-
associated cancers is, however, questionable, since increased incidences of lymphoma, 
the tumour most closely associated with depressed immune function, have not been 
reported among heavy drinkers (Blot, 1992). 
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2.9. ORGAN TOXICITY OF ACETALDEHYDE 
 
Nearly every organ system in the human body can be affected by heavy and prolonged 
use of alcohol. In addition to GI-tract cancers, there is no doubt that the consumption of 
alcoholic beverages increases the risk of alcoholic liver diseases. As already mentioned, 
ethanol itself is not carcinogenic. Similarly, the fact that only a minor proportion of 
alcohol abusers develop the most severe forms of liver damage suggests that other 
mechanisms than the direct effect of ethanol in creating tissue toxicity have to exist. 
Acetaldehyde, the first metabolite of ethanol, possesses toxic properties that markedly 
exceed those of ethanol, and there is increasing evidence suggesting its part in the 
detrimental action of alcohol on the digestive tract.   
 
Acetaldehyde-protein adducts 
 
Acetaldehyde has properties that make it very suitable for potential nucleophilic attacks. 
Since many nucleophilic groups are present in the proteins, they are natural targets in 
various tissues for reactive acetaldehyde. The binding of acetaldehyde with proteins 
results in the formation of two major types of product, which have been classified as 
unstable and stable acetaldehyde-protein adducts. The unstable adducts may serve as 
intermediates in stable adduct formation and can be stabilized by reducing agents such 
as NADH, which is found in large amounts in the liver during ethanol metabolism. The 
stable adducts appear to be the most likely causes of toxic effects (Nicholls et al., 1992).  
 
In vitro, acetaldehyde has been shown to bind covalently to many cellular and 
extracellular proteins (Nicholls et al., 1992). In vivo, it is well established that 
acetaldehyde adduct formation occurs in the liver during ethanol oxidation in both 
experimental animals and humans (Lin et al., 1988; Niemelä et al., 1991). To localize 
acetaldehyde-protein adducts, immunohistochemical studies have been performed with 
specific antibodies. Adducts have been demonstrated mainly in the cytoplasm of the 
perivenular hepatocytes, where acetaldehyde production is believed to be the highest 
(Niemelä et al., 1991, 1994). Moreover, acetaldehyde adducts have been detected in the 
areas of active fibrogenesis in the liver biopsy specimens from alcoholic patients 
(Holstege et al., 1994). More recently, acetaldehyde adducts have also been 
demonstrated in the rough endoplasmic reticulum (RER), and in some peroxisomes of 
hepatocytes, as well as in myofibroblasts and Ito cells (Paradis et al., 1996).  
 
Although the ability of acetaldehyde to bind to hepatic proteins during ethanol 
metabolism has been well established, the precise role of acetaldehyde-protein adducts 
in the pathogenesis of alcoholic liver disease has not been clarified. One mechanism 
through which such adducts may be involved in alcoholic liver disease is that 
acetaldehyde-protein adducts may be recognized as neoantigens by the immune system. 
This may trigger potentially harmful immune responses directed against liver cells 
(Nicholls et al., 1992). The presence of circulating antibodies against acetaldehyde-
protein adducts have indeed been described in humans (Israel et al., 1986; Niemelä et 
al., 1987). As several observations indicate that immunological mechanisms are 
involved in alcoholic liver disease, the appearance of such antibodies against 
acetaldehyde-protein adducts may be involved in the development and progression of 
liver injury (Tuma and Klassen, 1992). 
 
Acetaldehyde-protein adducts may also alter the biological properties of the modified 
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proteins. In the case of hepatic enzymes, the covalent binding of acetaldehyde has been 
shown to lead to the inhibition of the activities of enzymes which contain lysine at the 
catalytic site (Mauch et al., 1986). Moreover, long-term ethanol consumption has been 
shown to produce a decrease in O6 -methylguanine transferase (O6 -MeGT) activity in 
rats in vivo (Garro et al., 1986). This has been shown to be due to the acetaldehyde-
cysteine adduct in the active site of the enzyme, and it occurs even at nanomolar 
acetaldehyde concentrations (Espina et al., 1988). O6 -MeGT is a DNA repair enzyme, 
which removes alkyl groups from the O6 position of guanine. Since alkylation at this 
position is associated with both mutagenesis and carcinogenesis (Kleihues et al., 1979; 
Lewis and Swenberg, 1980; Newbold et al., 1980), the inhibition of O6 -MeGT offers 
one explanation of how ethanol may act as a cocarcinogen, enhancing the carcinogenic 
potential of other agents. 
 
There is not much evidence about acetaldehyde-protein adducts in the mucosa of the 
gastrointestinal tract. One study shows that both exogenous acetaldehyde and that 
produced locally from ethanol binds to gastric mucosa. This adduct formation has been 
suggested to be a pathogenetic factor behind ethanol-associated gastric injury (Salmela 
et al., 1997). No evidence indicates whether acetaldehyde adducts are formed in the 
mucosal proteins in the rest of the digestive tract or not. Since microbes produce high 
levels of acetaldehyde from ethanol in the oral cavity and the colon, similar adduct 
formation at these anatomical sites as in the gastric mucosa might also occur.  
 
Acetaldehyde as a carcinogenic agent 
 
Acetaldehyde has been shown to be a highly mutagenic agent. Specifically, it may 
induce chromosomal aberrations, and micronuclei and/or sister chromatid exchanges in 
cultured mammalian cells (Dellarco, 1988; IARC, 1985). Moreover, it has been shown 
to induce gene mutations in human lymphocytes (He and Lambert, 1990). The induction 
of cytogenetic effects has been postulated to be related to the ability of acetaldehyde to 
form DNA-DNA and/or DNA-protein cross-links. The mechanisms of these DNA 
cross-links caused by acetaldehyde may involve direct attack by acetaldehyde on DNA. 
A series of studies has shown that acetaldehyde can react with DNA bases to produce 
specific types of base adduct, which is a critical initiating event in the multistage process 
of chemical carcinogenesis (Hemminki and Suni, 1984; Vaca et al., 1995). Under 
biologically relevant conditions, the most prevalent of these is N2 -ethyl-
deoxyguanosine (N2 -Et-dG) (Fang and Vaca, 1995; Vaca et al., 1995).  
 
Fang and Vaca demonstrated that N2 -Et-dG becomes detectable in the liver DNA of 
mice treated with 10% ethanol in their drinking water for 5 weeks. This adduct was 
undetectable in control mice not given alcohol (Fang and Vaca, 1995). In humans such 
adducts have been detected in peripheral white blood cells of alcohol abusers (Fang and 
Vaca, 1997). DNA adducts have also been identified in nontumoral colon mucosa of 
human patients with colorectal cancer (Pfohl-Leszkowicz et al., 1995). Although these 
DNA adducts were unspecified and not necessarily related to acetaldehyde, this study 
indicates that covalent modification of DNA by xenobiotics may be involved in 
chemical carcinogenesis. Moreover, acetaldehyde-DNA adducts have also been detected 
in human buccal cells exposed to acetaldehyde in vitro (Vaca et al., 1998).  
 
There is sufficient evidence for the carcinogenicity of acetaldehyde to experimental 
animals (IARC, 1985). Acetaldehyde has been tested for carcinogenicity in rats and 
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hamsters by inhalation exposure. In such experiments, an increased incidence of 
carcinomas was observed in the nasal mucosa of rats (Woutersen et al., 1984), and 
laryngeal carcinomas were induced in hamsters (Feron et al., 1982). Moreover, in rats 
given either tap water or water containing acetaldehyde at a concentration of 120 mM, 
marked histopathological hyperplastic and hyperproliferative changes in the tongue, 
epiglottis, and forestomach were noted in the animals receiving acetaldehyde. These 
changes mimic those known to occur after treatment with alcohol (Homann et al., 
1997b). 
 
Lipid peroxidation 
 
A free radical is generally defined as a molecule that contains one or more unpaired 
electrons. As the presence of unpaired electrons usually confers a large degree of 
chemical reactivity on the molecule, most free radicals (superoxide and hydroxyl 
radicals) may lead to cell injury by abstracting a hydrogen atom from a polyunsaturated 
fatty acid, and thus initiating the degradative process known as lipid peroxidation. Since 
lipids are major components of biological membranes, peroxidative loss of membrane 
integrity has been thought to lead to tissue injury (Mufti et al., 1993). Glutathione is 
present in all animal cells in high concentrations, and one of its functions is the 
protection of cells against free radicals. A severe reduction in the levels of glutathione 
has been shown to increase lipid peroxidation in vivo (Lieber, 1988; Wendel et at., 
1979). 
 
Enhanced lipid peroxidation has been suggested as a mechanism for ethanol-associated 
liver injury (Situnayake et al., 1990). During ethanol oxidation reactive oxygen 
intermediates are produced by the MEOS. Acetaldehyde can also induce lipid 
peroxidation, as demonstrated in isolated perfused livers (Müller and Sies, 1982). The 
mechanism underlying this may be acetaldehyde’s capacity to reduce hepatic glutathione 
levels (Shaw et al., 1981). In addition, the incubation of rat liver supernatant with 
acetaldehyde results in the conversion of xanthine dehydrogenase to xanthine oxidase, 
an enzyme known to be able to generate superoxide radicals (Sultatos, 1988). Whether 
ethanol administration enhances in vivo lipid peroxidation has long been debated, but 
studies done on laboratory animals (Niemelä et al., 1995; Shaw et al., 1981) and humans 
(Niemelä et al., 1994; Shaw et al., 1983) point to this ability. Moreover, high 
acetaldehyde concentrations administered to rats have been shown to result in the 
formation of free radical reactions in vivo (Reinke et al., 1987). Taken together, ethanol-
derived acetaldehyde may lead to a severe reduction in glutathione, which favours lipid 
peroxidation, and the damage is possibly further enhanced by the increased generation 
of active radicals through induced MEOS following sustained ethanol consumption. 
 
Lipid peroxidation products, which result from the attack of reactive oxygen species on 
lipids, also react with DNA, forming ethenobases and adducts with known 
carcinogenicity and miscoding potential. Thus, during chronic alcohol abuse, where 
levels of reactive oxygen species and lipid peroxidation products are elevated and 
antioxidant levels are reduced, there is potential for significant damage to DNA and the 
production of DNA adducts that can compromise cellular function and may lead to 
oncogenic transformation (Brooks, 1997). 
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Evidence in humans 
 
Acetaldehyde exposition studies with humans are nowadays naturally forbidden. In the 
past, however, these have been done. Human volunteers exposed for 15 min to 
acetaldehyde vapour (90 mg/m3) experienced mild eye irritation. Men exposed to a 
higher concentration of acetaldehyde (360 mg/m3) for the same time developed 
transient conjunctivitis. Moreover, all 14 men exposed to 241 mg/m3 of acetaldehyde 
for 30 min developed mild upper-respiratory tract irritation (IARC, 1985).  
 
Indirect but stronger evidence for acetaldehyde as the major factor behind ethanol-
associated carcinogenesis is derived from recent studies linking the genotypes of 
ethanol- and acetaldehyde-metabolizing enzymes with enhanced tumour risk. Rapid 
metabolizing alcohol dehydrogenases (ADH3), leading to higher and quicker production 
of cellular acetaldehyde (Harty et al., 1997), and the lack of a low-km aldehyde 
dehydrogenase (ALDH2), leading to a longer and delayed exposure to acetaldehyde 
(Yokoyama et al., 1996a, b, c), have both been shown to be associated with an increased 
cancer risk in the oropharynx and esophagus. In a recent study among Orientals, the 
association between ALDH2 genotype mutation and cancer risk in alcoholics has been 
expanded to all possible alcohol-related cancers. In this study, the frequencies of the 
mutant ALDH2*2 allele were significantly higher in alcoholics with oropharyngeal, 
laryngeal, esophageal, stomach, colon and lung cancer, but not with liver or other 
cancers (Yokoyama et al., 1998). The relationship between alcohol consumption, 
ALDH2 heterozygocity, and the risk of colon cancer has also been confirmed very 
recently by others (Murata et al., 1999) as well as the lack of risk of alcohol-associated 
hepatocellular carcinoma in ALDH2 heterozygotes (Takeshita et al., 2000). 
 
So far this phenomenon has been thought to arise from systemic effects of elevated 
blood acetaldehyde (Yokoyama et al., 1996a, b, c). Interestingly, however, all the organs 
with enhanced cancer risk are covered by microbes. It is therefore possible that the 
impaired detoxification of acetaldehyde in ALDH2 deficient subjects might become 
clinically relevant only in cases of marked acetaldehyde production by microbes. This 
hypothesis is strongly supported by our very recent finding demonstrating that Asians 
with mutant ALDH2*2 allele had 2-3 times higher in vivo salivary acetaldehyde levels 
after a moderate dose of ethanol than those Asians with a normal ALDH 2*1 genotype 
throughout the whole follow-up period of 240 minutes. The in vitro capacity of saliva to 
produce acetaldehyde from ethanol was equal in these two groups, which suggests that 
there were no obvious difference in the capacity of the oral flora to produce 
acetaldehyde from ethanol between the groups. The subjects with the mutant ALDH2*2 
allele appeared to be able to produce higher in vivo salivary levels of acetaldehyde 
because their parotid glands also contributed to acetaldehyde production, a phenomenon 
that did not occur in subjects with the normal genotype. Possible differences in the 
capacity of the oral mucosa to metabolise acetaldehyde further to acetate might also 
explain this (Väkeväinen et al., 2000). This study, together with earlier epidemiological 
findings, provides strong evidence for the local carcinogenic potential of acetaldehyde in 
humans 
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3. AIMS OF THE STUDY 
 
 
Alcohol consumption has increased in Finland from the late 1960's. Alcohol-related 
gastrointestinal disorders and organ injuries are consequently an increasing health 
problem. Relatively little is, however, known about their pathogenesis. Ethanol per se 
appears to be unable to cause most of them. 
 
During recent years it has become evident that microbes representing the normal flora of 
the alimentary tract participate in the metabolism of exogenous ethanol. Consequently, 
high levels of acetaldehyde are produced in those parts of the GI tract that hold the 
largest number of microbes - the oral cavity and colon. Because of its high toxicity and 
carcinogenic potential, acetaldehyde can be expected to cause organ damage wherever it 
exists at high concentrations. 
 
Understanding of the mechanisms behind alcohol-associated gastrointestinal morbidity 
could be helpful in their management and a prerequisite for their prevention. Research 
aimed at exploring those mechanisms is therefore justified. 
 
 
The specific aims of the study were: 
 
1. To study the enzymatic mechanisms underlying acetaldehyde production from   
 ethanol by human colonic contents. 
  
2. To evaluate the role of microbial ethanol oxidation in ethanol metabolism in 
 humans. 
 
3. To explore the effect of antibiotic treatment on the formation of acetaldehyde in the 
gastrointestinal tract and to clarify the bacterial species responsible for the    
 intracolonic acetaldehyde production from ethanol. 
 
4. To study the effect of chronic ethanol treatment on intracolonic acetaldehyde levels 
in rats. 
 
     5.    To investigate the effect of folate depletion on the carcinogenic action of acetaldehyde. 
 
     6.    To elucidate the factors and microbial species which regulate the microbial   
      production of acetaldehyde from ethanol in the oral cavity of humans. 
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4. MATERIALS AND METHODS 
 
 
4.1. ETHICAL CONSIDERATIONS 
 
In the studies with humans volunteers (I, II, V, VI) informed consent was given, after approval 
by the Ethical Committee at the Helsinki University Central Hospital. The rat studies were 
approved either by the ethical committee of the Helsinki University Central Hospital (III) or by 
the Committee on Animal Experimentation of the County Council (IV). Animal studies were 
performed according to the institutional guidelines and principles of the Animal Care Unit of 
the University of Helsinki.  
 
 
4.2. ACETALDEHYDE PRODUCTION BY HUMAN COLONIC CONTENTS IN 
VITRO (I) 
 
Collection of colonic contents 
  
Colonic contents were collected from 14 Finnish patients undergoing colonoscopy for lower 
GI symptoms. The age of the patients ranged from 29 to 74 years (mean 51 years). The 
exclusion criterion was the use of antibiotics during the period of 4 weeks preceding the 
colonoscopy. During the colonoscopy, approximately 10 ml of colonic content was aspirated 
through a fiberoscope from the caecum and transverse colon. The samples were frozen 
immediately at -80 C pending analysis. 
 
Determination of acetaldehyde production in vitro 
 
Samples were first lyophilized for 24 hr, whereafter the dry mass was dissolved in 100 mM of 
potassium phosphate buffer (pH 7.4) at a concentration of 10 mg/ml, except when studying the 
effect of different quantities of the colonic contents. 400 µl of resuspended colonic content was 
transferred into a gas chromatographic vial, and 50 µl of potassium phosphate buffer (final 
concentration 100 mM, pH 7.4) containing ethanol (final concentration 22 mM) was added and 
the vials were immediately tightly closed. The vials were incubated for 60 min at 37 C. The 
effect of different incubation times, increasing ethanol concentrations and different amounts of 
colonic contents on acetaldehyde production were also tested.  
 
To study the effect of different enzyme inhibitors, Sodium azide (SA, a catalase inhibitor), 3-
amino-1,2,3-triazole (3-AT, a catalase inhibitor), 4-methylpyrazole (4-MP, an ADH inhibitor), 
or metyrapone (a MEOS inhibitor) were added at increasing concentrations 15 min prior to 
ethanol/buffer mixture to the vials containing colonic contents.  
 
To confirm catalase and ADH as the enzymes responsible for acetaldehyde production, 
increasing concentrations of the hydrogen peroxide generating system (final glucose 
concentration 10 mM, glucose oxidase 0.003 - 0.3 µmol/min) or exogenous NAD (final 
concentration 1 - 10 mM) were added to the incubation mixture.  
 
After incubations reactions were stopped by injecting 50 µl of 6 mol/l perchloric acid (PCA) 
through the rubber septum of the vial. Acetaldehyde was analysed by head space gas 
chromatography as described in chapter 4.8. 
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Analyses of catalase activity 
 
To prepare supernatant for measurement of enzyme activity, the colonic contents were 
dissolved in 100 mM potassium phosphate buffer and first sonicated. This was followed by 
centrifugation of the sonicate at 100,000 g at 5 C for 60 minutes. Catalase activity was 
determined spectrophotometrically at 240 nm after the addition of 10 mM of H2O2 at 37 C. 
Catalase activity was related to the protein concentration of the supernatant (Lowry et al., 
1951). 
 
 
4.3. THE EFFECT OF CIPROFLOXACIN ON ETHANOL ELIMINATION IN 
HUMANS (II) 
 
Volunteers 
 
Eight healthy Caucasian males (age range of 21-31 years, mean BMI 23.8 ± 0.4 kg/m2) 
participated in the study. None of the subjects had received any antibiotics for four weeks 
preceding the study. The volunteers’ weekly average consumption of alcohol was about 70 
grams of ethanol. All participants were told to refrain from ethanol for at least 36 hours before 
the study. 
 
Study design 
 
The design was open, non-randomized, and non-placebo controlled, each subject serving as his 
own control. The two study days were separated by a 1-week interval, and the protocol was 
exactly the same on both occasions. Two intravenous lines were placed in the antecubital 
veins, one for the administration of ethanol and one for obtaining blood samples. Ethanol (0.63 
g/kg body weight) was mixed in 5% glucose solution at 7% v/v concentration and was 
administered intravenously at a constant rate over a 30-min period. Repeated blood samples (3 
ml) were taken into vacutainer tubes for measurements of blood alcohol level by head space 
gas chromatography. Baseline samples were taken before ethanol administration had started 
(time 0) and at five minute intervals during the first hour, at 15 minute intervals during the 
second hour, and at 20 minute intervals until the breath ethanol analyser showed no detectable 
blood ethanol levels. For seven days between the experiments, the volunteers received 750 mg 
ciprofloxacin orally twice a day. 
 
Pharmacokinetic calculations of ethanol in blood 
 
The concentration-time profiles of ethanol were evaluated according to zero-order kinetics. 
The y-intercept of the regression line (C0) is the concentration of ethanol in blood if the dose 
of 0.63 g/kg was distributed into total body water immediately after the infusion started. The 
ratio of the dose of ethanol (g/kg) divided by the parameter C0 is the apparent volume of 
distribution of ethanol (Vd). The ethanol elimination rate (EER) from the body was obtained 
by dividing the dose given by the estimated time of reaching zero concentration of ethanol in 
blood (time0). The time0 parameter corresponds to the x-intercept of the concentration-time 
regression equation. The areas under the concentration-time profiles (AUCs) were determined 
by the trapezoidal method (Rangno et al., 1981).   
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The effect of ciprofloxacin on human hepatic ADH in vitro 
 
A piece of human liver tissue was obtained from a patient undergoing surgery. The tissue was 
first homogenised 1:4 with 100 mM potassium phosphate buffer, pH 7.4. The homogenate was 
centrifuged at 1000 g at 4 C for 10 min, followed by centrifugation at 100,000 g at 5 C for 60 
min to obtain the cytosolic fraction. Hepatic ADH activity was determined 
spectrophotometrically by monitoring the formation of NADH at 340 nm at 37 C. The ADH 
activity of cytosolic fraction was measured in 100 mM potassium phosphate buffer containing 
3 mM of NAD and 25 mM of ethanol. The effect of ciprofloxacin on ADH activity was tested 
by adding increasing drug concentrations to the buffer (final concentrations 0, 1, 10, 20 µg/L). 
 
 
4.4. THE EFFECT OF CIPROFLOXACIN ON HUMAN FAECAL FLORA AND 
ACETALDEHYDE PRODUCTION (II) 
 
Microbial analysis 
 
The faecal samples were thawed, and 1 gram of each specimen was suspended and serially 
diluted (10-fold)  in peptone yeast extract broth. The undiluted sample and a 10 µl aliquot of 
the appropriate dilutions were inoculated and spread on several selective and non-selective 
agar media for the enumeration and isolation of total counts and main groups of aerobic and 
anaerobic bacteria and yeasts. The aerobic plates were incubated at 35 C in an atmosphere 
containing 5% CO2 for up to 5 days; anaerobic plates were incubated in anaerobic jars filled 
by the evacuation replacement method with mixed gas (90% N2, 5% CO2, 5% H 2) up to 14 
days for the final inspection. The bacteria were enumerated and identified by established 
methods (Murray et al., 1999; Summanen et al., 1993). 
 
Determination of faecal ADH and catalase activity 
 
Faecal samples were collected before and after the ciprofloxacin treatment from the volunteers 
described in 4.3. Samples were frozen at -80  for further analysis. Supernatant from lyophilized 
faecal samples was prepared, and the ADH activity of the supernatant was determined as 
described in 4.3. Catalase activity was determined as described in 4.2. Enzyme activities were 
related to the protein concentrations of the supernatant (Lowry et al. 1951). 
 
Faecal acetaldehyde production in vitro 
 
250 µl of supernatant was transferred into a gas chromatography vial, and 200 µl of potassium 
phosphate buffer (final concentration 100 mM, pH 7.4) containing ethanol (final concentration 
22 mM) and different coenzymes (NAD or glucose + glucose oxidase or both) was added and 
the vials were closed. The vials were incubated for 60 minutes and the reaction was stopped by 
PCA. Acetaldehyde production was related to the protein concentration of the supernatant 
(Lowry et al., 1951).  
 
 
4.5. SUSTAINED ETHANOL AND METRONIDAZOLE TREATMENT IN RATS (III) 
 
Animals and study protocol 
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Male Wistar rats (strain Hsd/wi barrier) were used and kept under conventional conditions.   
 
To study the effect of long-term ethanol administration and metronidazole treatment on 
ethanol and acetaldehyde metabolism in rats, 32  rats were housed individually in stainless-
steel wire-bottomed cages. When the rats reached an average weight of 190 ± 1 g they were 
switched to a liquid diet (Lindros and Järveläinen, 1998) This was the control diet. After two 
days adaptation, the rats were divided into 4 groups as follows.  
 
Group 1 (C, control, n=6)  Control diet, pair-fed to 3 
Group 2 (CM, n=6)   Control diet + metronidazole 50 mg/kg b.w./day, pair-fed to 4 
Group 3 (E, ethanol, n= 10)  Ethanol diet ad libitum 
Group 4 (EM, ethanol metronidazole, n=10) Ethanol diet ad libitum + metronidazole 50 mg/kg b.w./day 
 
The ethanol content of the diet was increased gradually up to the final 5% w/v. The diets were 
renewed every 24 h at 9.00. Diet intake was recorded daily and weight gain twice a week. The 
rats were maintained on pair-feeding for 6 weeks. 
 
Blood ethanol and acetaldehyde analysis 
 
To measure diurnal blood ethanol concentrations, tail-vein blood samples (50µl) were taken 
from rats receiving ethanol on four different days at 6.00, 12.00, 18.00, and 24.00 and 
haemolysed in 450 µl of ice-cold water. Terminal blood was taken by heart puncture. Blood 
ethanol and acetaldehyde levels were determined by head-space gas chromatography. 
 
Colonic ethanol and acetaldehyde levels 
 
Caecal samples were diluted 1:6 with distilled ice-cold water and mixed carefully. An aliquot 
of 450 µl was pipetted into gas chromatographic vials and immediately mixed with 50 µl of 6 
mol/l PCA. Intestinal ethanol and acetaldehyde levels were analysed by head space gas 
chromatography. 
 
Preparation of the tissues for enzyme determination 
 
Before enzyme analyses, livers were perfused in situ with saline, and samples were transferred 
to - 80 C pending analysis. Ice-cold medium containing 0.25 M of sucrose, 5 mM of Tris, and 
0.5 mM of EDTA (pH 7.2) was then added to the tissues in an amount making the tissue 
constitute 15 to 20% of the total. This was followed by homogenization and sonication for 9 x 
5 sec at +4 C. The homogenate was centrifuged at 700 g for 15 min to remove unbroken cells 
and nuclei and the supernatant was used for all enzyme assays.  
 
The colons were washed with cold saline and the mucosal layers collected by gentle scraping. 
To analyse enzyme activity, mucosa of the large intestine were handled as described above.  
 
Determination of ALDH and ADH activity 
 
Hepatic and colonic mucosal ALDH and ADH activities were determined 
spectrophotometrically by measuring the formation of NADH at 340 nm at 25 C. The ALDH 
activity of the supernatant was assayed in 60 mM of sodium pyrophosphate buffer (pH 8.8) 
containing 0.5 mM of NAD, 0.1 mM of 4-MP, 2 µM of rotenone, and either 100 µM (low Km 
activity) or 5 mM (total activity) of acetaldehyde. The ADH activity of cytosolic fractions was 
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measured in 100 mM glycine buffer (pH 9.6) containing 1 mM of NAD, 2 µM of rotenone, 
and 25 mM of ethanol. The protein concentration was determined by the Bio-Rad method 
(Bio-Rad protein assay, Hercules, USA). 
 
Microbial analysis 
 
Caecal content microbial analysis was carried out as described in chapter 4.4. 
 
 
4.6. THE EFFECT OF ACETALDEHYDE ON INTESTINAL FOLATE LEVELS IN 
RATS (IV) 
 
Animals and study protocol 
 
The animals were male Wistar rats (strain Hsd/wi barrier). 
 
To study the effect of ethanol-derived acetaldehyde on intestinal folate levels, 40 rats were 
randomly divided into 4 groups as follows.  
 
Group 1 (saline, n=10)  Intragastric (ig incubation 2x/day with saline 
Group 2 (Saline/Cipro, n=10)  Ig incubation 2 x/day with saline and ciprofloxacin 50 mg/kg  
Group 3 (Ethanol, n=10)  Ig incubation 2 x/day with ethanol 3g/kg b.w. as 38% v/v 
Group 4 (Ethanol/Cipro, n=10)  Ig incubation 2 x/day with ethanol and ciprofloxacin as above 
 
 
Intubations were carried out with the same volume in every group for 14 days. Rats had free 
access to tap water and standard chow (Altromin Nr 1324 Pellets, Lage, Germany) with a 
folate content generally accepted as meeting the basal dietary requirement for a rat (2mg folate/ 
kg diet) (Reeves et al., 1993). The general condition, body weight, and food intake were 
recorded daily. Rats were killed after anasthesia with 1 mg/kg phenobarbital on day 14 of the 
study, 45 minutes after the last intubation. 
 
Blood ethanol analysis 
 
Terminal blood ethanol levels were determined by head-space gas as described in 4.5.  
 
Colonic and small intestinal ethanol and acetaldehyde levels 
 
The small intestinal content, obtained 40 cm caudal from the stomach, and caecal contents 
(about 1.5 ml) were transferred into Eppendorf tubes containing 50 µl of PCA. Thereafter 
contents were spun down by centrifugation at 2400 g for 20 sec. An aliquot of 475 µl of the 
supernatant was immediately transferred into a gas chromatographic vial containing 25 µl of 
PCA. Intestinal ethanol and acetaldehyde levels were analysed by head space gas 
chromatography. 
 
Preparation of the tissues for folate analysis 
 
For folate measurements small intestinal and colonic mucosa were transferred to pre-weighed 
Eppendorf tubes. Thereafter, the wet weight of the scraped mucosa was overlaid with ten 
volumes of folate-lysis buffer (Kim et al., 1996). Folate glutamates were cleaved and 
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transferred by incubation with folate-free chicken pancreas conjugase, then stored at –70 C 
until analysed (Kim et al., 1996). 
 
Folate analysis 
 
Serum and erythrocyte folate levels were measured by conventional enzymatic methods 
following the manufacturer’s instructions (Simultrac Radioassay Kit, ICN Pharmaceuticals, 
NY, USA), and taking the current hematocrit value into account. The folate content of the gut 
mucosa was measured by enzymatic methods using the same kit as for the serum folate. The 
folate levels of the intestine was related to the mucosal protein content (Bio-Rad protein assay, 
Hercules, USA).     
 
 
4.7.  HUMAN SALIVA STUDIES (V, VI) 
 
Subjects 
 
A total of 326 Caucasian volunteers participated in the studies. This cohort consisted of 114 
healthy volunteers, 122 patients seeking dental examination or treatment, 26 patients with a 
malignant tumour of the oral cavity (11 were untreated and 15 were in the follow-up stages), 
and 64 alcoholics recruited from a municipal alcohol detoxification clinic. 
 
Questionnaire 
 
A questionnaire was answered by each volunteer. Information concerning age, gender, tobacco 
use, alcohol use, diet, oral health status, oral hygiene habits and other characteristics were 
elicited. Tobacco use indicators included the average number of cigarettes smoked per day 
within the past 30 days, duration of smoking in years, and the date when a possible smoking 
cessation may have occurred. The daily tobacco consumption was calculated as cigarettes 
smoked per day. Alcohol consumption was estimated as the average number of drinks ingested 
(about 12g of pure alcohol) for every drinking day during the past 30 days and as the frequency 
of alcohol intake per week. The average amount of alcohol consumed as grams of pure ethanol 
per day was calculated from this data. Volunteers were ranked as non-drinkers (less than 1 
gr/day), moderate drinkers (1-30 gr/day for females, 1-40 gr/day for males) or heavy drinkers 
(>30 gr/day for females, >40 gr/day for males). 
 
Salivary samples 
 
Stimulated whole saliva was collected between 9 and 12 a.m. after one minute’s use of a 
paraffin chewing gum (Orion Diagnostics, Espoo, Finland), and was immediately frozen at -70 
C. Exclusion criteria were as follows: treatment with oral antiseptic or antibiotics in the past 
month, food or fluid intake, smoking or toothbrushing in the previous 90 minutes, recent 
alcohol intake or a measurable amount of alcohol in the saliva by head space gas 
chromatography. 
 
Determination of salivary acetaldehyde production capacity 
 
Saliva was thawed and preheated to 37 C before analysis. 400 µl of saliva was transferred into 
a gas chromatography vial, and 50 µl of potassium phosphate buffer (final concentration 100 
mM, pH 7.4) containing ethanol (final concentration 22mM) was added and the vials were 
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immediately tightly closed. The vials were incubated for 90 minutes and the reaction was 
stopped by injecting 50 µl of PCA, whereafter acetaldehyde was analysed using head space gas 
chromatography. 
 
Salivary microbiological analysis 
 
Among all 326 volunteers, the 10 saliva samples with the lowest and the highest acetaldehyde 
production were chosen for microbial analysis (V). Since this analysis revealed that yeasts 
were found in higher concentrations and more frequently among the subjects with higher 
acetaldehyde production, all the saliva samples with acetaldehyde production of more than 250 
µM (23 samples) or less than 40 µM (32 samples) were used to assess the prevalence of yeasts 
(VI). 
 
The saliva samples were thawed, and serially diluted  in peptone yeast extract broth. A 10 µl 
quantity of undiluted sample and the appropriate dilutions were inoculated on several selective 
and nonselective agar media for the enumeration and isolation of aerobic and anaerobic 
bacteria and yeasts. The aerobic plates were incubated at 36 C in an atmosphere containing 5% 
CO2 for a total of 5-7 days, and anaerobic plates in anaerobic jars filled with the evacuation 
replacement method with mixed gas (85% N2, 10% CO 2, 5% H 2) were incubated up to 14 
days for the final inspection. Bacterial counts were determined by multiplying the number of 
colonies by the dilution factor, adjusted for inoculation volume (V). Yeast colonies (VI)  were 
enumerated and identified by germ tube test and by API ID 32 C (bioMérieux, Marcy l’Etoile, 
France). The yeast cultures were then harvested three times before yeast suspensions were 
prepared. The actual number of viable yeasts, expressed as colony forming units (CFU/ml), in 
the vials was determined by quantitative viable count (VI).  
 
Acetaldehyde production by isolated yeast strains 
 
Acetaldehyde analysis was carried out as with the saliva samples, except the incubations were 
carried out for 60 minutes. 
 
 
4.8. GAS CHROMATOGRAPHIC MEASUREMENTS OF ETHANOL AND 
ACETALDEHYDE 
 
Acetaldehyde production from ethanol by colonic contents in vitro (I), faecal samples in vitro 
(II), caecal samples in vivo (III, IV), salivary samples in vitro (V), and isolated oral yeasts (VI) 
was analysed using head space gas chromatography by heating the vials to a temperature of 37 
C as reported earlier (Pikkarainen et al., 1979). The conditions for analysis were: Column 
60/80 Carbopack B/5% Carbowax 20M, 2 m x 1/8" (Supelco Inc, Bellefonte, PA, USA); oven 
temperature, 85 C; transfer line and detector temperature, 200 C; carrier gas flow rate (N2), 20 
ml/min. Acetaldehyde production after certain incubation times in vitro (I, II, V, VI) or in in 
vivo studies immediately after collection was stopped with PCA. 
 
An artifactual formation of acetaldehyde from ethanol prior to the headspace analysis 
(Eriksson and Fukunaga, 1993) is a problem associated with analysis of acetaldehyde in 
biological fluids. Precipitation of proteins results in the non-enzymatic production of 
artifactual acetaldehyde, an effect that cannot be completely eliminated, even by centrifugation 
and removal of the protein precipitates (Sippel, 1972; Stowell et al., 1977). Several analytical 
modifications have been described in order to minimize artifactual acetaldehyde formation;  
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nevertheless, parallel analyses with control samples using corresponding ethanol 
concentrations should be carried out (Eriksson and Fukunaga, 1993). 
 
To control for non-enzymatic artifactual acetaldehyde formation from ethanol during the 
protein precipitation, perchloric acid was added simultaneously with ethanol into additional 
incubation vials (incubation time 0). The acetaldehyde concentrations of these control samples 
were subtracted from acetaldehyde values obtained after longer incubation periods (I-VI).   
 
 
4.9. STATISTICAL ANALYSIS 
 
All results are expressed as means ± SEM (I-VI). To test the effect of drugs or conditions on 
acetaldehyde production ANOVA for repeated measures, followed by Bonferroni’s t test was 
used (I). The possible statistical significance of the differences before and after the 
ciprofloxacin intake was analysed by Student’s t test (II). In the animal studies the differences 
between the groups were analysed by ordinary ANOVA, followed by the Tukey-Kramer 
Multiple Comparison Test. Logarithmic transformation was performed when appropriate (III, 
IV). To analyse the effect of various factors on salivary acetaldehyde production, a Spearman 
correlation matrix was computed for the entire study population as a preliminary analysis. This 
was followed by multivariate regression analyses. As co-linearity was obvious for smoking and 
heavy alcohol intake, the multivariate analyses were re-run for non-smokers and for moderate 
and non-drinkers in order to adjust for this confounding factor. A multiple linear regression 
analysis, a forward stepwise regression analysis (r2 as the best criterion) was run with the best 
descriptor for all variables, setting acetaldehyde production as the dependent variable (V). 
When the statistical significance of the differences between “high” and “low” acetaldehyde 
producers was compared, the nonparametric unpaired Mann Whitney U test was used (V, VI). 
Fisher’s exact test was used to identify possible differences in the presence of yeasts between 
two groups (VI). 
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5. RESULTS 
 
 
5.1. ENZYMATIC PRODUCTION OF ACETALDEHYDE BY HUMAN COLONIC 
CONTENTS IN VITRO (I) 
 
The amount of acetaldehyde produced by the human colonic content was proportional to the 
ethanol concentration, the amount of colonic content, and the length of the incubation time.   
Both catalase inhibitors, SA and 3-AT, reduced the amount of acetaldehyde produced from 
ethanol in a concentration dependent manner as compared to the control samples (Fig. 1). SA 
decreased the acetaldehyde production (by 26.4 ± 6.9%) significantly at a concentration of 0.1 
mM and 3-AT (by 32.6 ± 13.0%) at a concentration of 10 mM. Metyrapone and 4-MP had no 
significant effect on acetaldehyde production under these conditions. 
   
Col 1 
A
ce
ta
ld
eh
yd
e 
pr
od
uc
tio
n 
(%
 o
f c
on
tro
l)
0
20
40
60
80
100
*
*
*
*
**
*
*
*
*
Sodium azide (mM) 3-amino-1,2,3-triazole (mM)
0.1 .5 1 5 10 501000 1 5 10 10050
 
Fig. 1. The effect of catalase inhibitors on acetaldehyde production by colonic contents during a 90 min 
 incubation with 22 mM ethanol. * p <0.05 compared to control. (Reproduced with permission from 
 Lippincott Williams & Wilkins). 
 
Exogenous hydrogen peroxide produced by the glucose + glucose oxidase system significantly 
increased acetaldehyde production, in proportion to higher glucose oxidase activity. The 
highest value was reached with 0.3 µmol/min glucose oxidase (677% ± 156 of the control) 
(Fig. 2). The acetaldehyde production was also increased after the addition of NAD. With 3 
mM NAD the acetaldehyde production was increased up to 5 times as compared to the 
controls.  
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Fig. 2. The effect of a H2O2 generating system  (glucose + glucose oxidase on acetaldehyde 
 formation during a 60 min incubation with 22 mM ethanol. * p < 0.05 compared to control.  (Reproduced 
with permission). 
 
 
The mean catalase activity of the supernatant was 0.53 ± 0.1 µmol/min/mg protein with 10mM 
H2O2. There was a significant correlation between catalase activity and acetaldehyde 
production by the supernatant in the presence of glucose + glucose oxidase (r=0.96, p<0.05) 
indicating the role of catalase in acetaldehyde production under these circumstances. 
 
 
5.2. THE EFFECT OF CIPROFLOXACIN ON ETHANOL ELIMINATION IN 
HUMANS (II) 
 
Table 2 summarizes the pharmacokinetic parameters of ethanol derived from blood 
concentration time data. The time to reaching zero ethanol concentration in blood (time0) 
increased after ciprofloxacin medication, and accordingly there was a highly significant 9.4% 
decrease (range 5.1% to 17.6%; p=0.001) in the ethanol elimination rate (EER).  
 
 
Table 2. Effects of ciprofloxacin on ethanol pharmacokinetics (mean±SEM) 
 
   
  Before Cipro After Cipro p 
    
Peak EtOH (mM) 22.5 ± 1.0 23.3 ± 1.3 n.s. 
Vd (l/kg) 0.70 ± 0.02 0.70 ± 0.02 n.s. 
C0 (mM) 19.7 ± 0.5 19.7 ± 0.6 n.s. 
EER (mg/kg/h) 107.0 ± 5.3 96.9 ± 4.8 0.001 
AUC (mM·h) 58.9 ± 2.9 65.5 ± 3.3 0.0004 
Time0 (h) 6.0 ± 0.3 6.6 ± 0.3 0.0003 
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5.3. THE EFFECT OF CIPROFLOXACIN ON HUMAN FAECAL FLORA AND 
ACETALDEHYDE PRODUCTION  (II) 
 
The effect on microbial flora 
 
Ciprofloxacin treatment for seven days produced a 17-fold decline in the total number of 
faecal aerobic bacteria. Enterobacteriaceae, the predominant aerobic flora present in every 
volunteer at the beginning of the study, disappeared from the faeces entirely after ciprofloxacin 
treatment. Enterococcus sp., which were found in five of the eight subjects before the 
ciprofloxacin intake, were also eradicated after the treatment. Other aerobic species responded 
variably. Yeasts appeared at low levels in two subjects after ciprofloxacin administration. The 
count of anaerobic bacteria declined slightly. This was mainly due to a drop in the number of 
Bifidobacterium species. The bacteriological data is seen in detail in the original article. 
 
The effect on faecal enzymes and acetaldehyde production  
 
The mean ADH activity of the faecal samples measured after the ciprofloxacin treatment was 
significantly lower at both 25 mM (p=0.013) and 1.5 M (p=0.006) ethanol concentrations than 
of the samples taken before the treatment. The ADH activity at both ethanol concentrations 
decreased approximately 60% after the treatment. The catalase activity, however, remained 
unchanged after ciprofloxacin dosing. The acetaldehyde production capacity of the faecal 
samples also decreased significantly (by 60%, p=0.007) after ciprofloxacin treatment when 
NAD was used as a cofactor to activate ADH, but remained unaltered when glucose + glucose 
oxidase was used to activate catalase. There was also a statistically significant correlation 
(r=0.75, p<0.001) between faecal ADH activity at 1.5 M ethanol and acetaldehyde production 
from ethanol. 
 
 
5.4. THE EFFECT OF SUSTAINED ETHANOL AND METRONIDAZOLE 
TREATMENT ON INTRACOLONIC ACETALDEHYDE PRODUCTION IN RATS 
(III). 
 
Animals 
 
All animals tolerated the six-week treatment period. However, the body weight decreased most 
in the rats receiving ethanol and metronidazole. The weight of the rats (initials-finals) were as 
follows: group 1 (C, control) 185±3 g - 214±3 g, group 2 (CM, control metronidazole) 188±3 
g - 206±3 g, group 3 (E, ethanol) 194±2 g - 177±7 g, group 4 (EM, ethanol metronidazole) 
192±3 - 146±5 g. 
 
Intracolonic ethanol and acetaldehyde concentrations 
 
Intracolonic terminal ethanol concentrations were comparable in groups E and EM (34.0±2.0 
mM and 36.8±0.6 mM respectively, n.s.). However, the rats in group EM had five times higher 
intracolonic acetaldehyde levels than those receiving only ethanol (431.4±163.5 µM and 
84.7±14.4 µM respectively, p<0.01, Fig. 3). 
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 Fig. 3. Intracolonic acetaldehyde levels in the study   
 groups (mean±SEM) 
 
 C= Controls 
 CM = Controls receiving metronidazole 
 E = Ethanol group 
 EM = Ethanol and metronidazole group 
 
 (Reproduced with permission from Lippincott Williams & Wilkins). 
 
 
Colonic mucosal ADH and ALDH activities 
 
Metronidazole treatment did not inhibit colonic mucosal ADH or ALDH activity. Indeed, 
colonic mucosal ALDH activity was found to be higher in the rats which received ethanol and 
metronidazole than the ethanol group (Table 3). 
 
 
Table 3. Colonic mucosal ADH and ALDH activities in the study groups (mU/mg) 
 
   
Group (n) ADH ALDH ALDH 
   (High Km) (Low Km) 
 
C (6) 4.8 ± 0.4 4.0 ± 0.4 1.3 ± 0.2 
CM (6) 6.7 ± 1.8 3.5 ± 0.4 1.9 ± 0.3 
E (10) 6.9 ± 1.0 4.2 ± 0.3 0.9 ± 0.2 
EM (10) 6.7 ± 1.5 6.6 ± 0.7*,** 2.2 ± 0.2***  
 
* p<0.05 compared to E 
** p<0.01 compared to CM 
*** p<0.001 compared to E 
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Bacteriological analysis of caecal contents 
 
Ethanol and metronidazole treatment led to 3-fold reduction in the total anaerobic caecum 
flora compared to the rats receiving only ethanol (p<0.05). Particularly the number of 
Bacteroides fragilis were reduced (p<0.01). By comparison, ethanol and metronidazole 
treatment produced a 18-fold increase in the number of total aerobes (p<0.01) compared to the 
ethanol group, and especially the number of Enterobacteriaceae (p<0.05) and  -haemolytical 
Streptococci (p<0.001) increased. It should also be noted that ethanol treatment alone 
increased significantly the number of total aerobes and Enterobacteriaceae as compared to the 
controls. The exact bacteriological counts are seen in the original article.  
 
 
5.5. THE EFFECT OF ETHANOL AND METRONIDAZOLE TREATMENT ON 
BLOOD ETHANOL AND ACETALDEHYDE LEVELS IN RATS (III) 
 
Ethanol intake, blood ethanol and acetaldehyde concentrations 
 
Ethanol intakes were equal in groups E and EM: 11.8±0.2 vs. 11.4±0.2 g/kg body wt. per day 
respectively (n.s.). Animals in groups E and EM were found to be ethanol-intoxicated 
throughout the 24 h period, and no significant differences in the diurnal blood ethanol levels 
between these groups could be detected during the trial. The terminal blood ethanol levels in 
groups E and EM were 38.0±1.8 mM and 42.1±2.0 mM respectively (n.s.). Terminal blood 
acetaldehyde levels were 7.0±0.3 µM in group E and 7.4±0.2 µM in group EM (n.s.).  
 
Liver ADH and ALDH activity 
 
Metronidazole treatment did not inhibit hepatic ADH or ALDH enzymes in a statistically 
significant way (Table 4.). 
 
 
Table 4. Hepatic ADH and ALDH activities in the study groups (mU/mg) 
 
 
   
Group (n) ADH ALDH ALDH 
   (High Km) (Low Km) 
 
C (6) 17.7 ± 1.3 9.2 ± 1.7 8.5 ± 1.3 
CM (6) 16.7 ± 1.6 7.6 ± 1.0 7.6 ± 0.7 
E (10) 16.2 ± 0.8 11.5 ± 1.0 6.5 ± 0.8 
EM (10) 15.5 ± 0.5 13.2 ± 0.9* 6.3 ± 0.6 
  
* p<0.05 compared to CM 
 
 
5.6. THE EFFECT OF ACETALDEHYDE ON INTESTINAL FOLATE LEVELS IN 
RATS (IV)  
 
Animals 
 
All animals tolerated the two weeks’ experiment, except of one rat from group 4 that died due 
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to the regurgitation of intubated solution. During the study, the rats in group 1 kept their 
weights, whereas there were significant weight losses (4 to 10 %, p<0.01) in the other three 
groups. However, the differences in the total body weight at the end of the experiment were 
not significant between the groups. 
 
Ethanol and acetaldehyde levels  
  
Mean blood ethanol concentration in the ethanol-treated rats was 34±5 mM in group 3 and 
33±5 mM in group 4 (n.s.). Intracolonic ethanol levels were also similar in groups 3 and 4 
(28±5 and 33±7 mM respectively, n.s.). There was a highly significant correlation between the 
individual blood ethanol and intracolonic ethanol levels (r=0.84, p<0.0001, data not shown). 
Small amounts of endogenous ethanol (1.4±0.3 mM) were detectable in the colon in the non-
ethanol-treated rats, and this was reduced by ciprofloxacin treatment to the level of 0.9±0.1 
mM (n.s.). Small intestinal ethanol levels in group 3 and 4 were similar.  
 
The local acetaldehyde levels in the colon after ethanol intake were strikingly high (387±185 
µM in group 3), which was significantly reduced (p<0.001) by concomitant ciprofloxacin 
treatment (Fig. 4). Also, substantial endogenous colonic acetaldehyde levels were detectable in 
control group 1 (59±14 µM), these being significantly reduced (p<0.001) by ciprofloxacin 
treatment (Fig. 4). Only traces of acetaldehyde were detectable in the small intestine in any of 
the groups.   
 
Folate levels 
  
Rats receiving ethanol had a significantly lower folate intake when assessed by average daily 
food intake than the rats receiving saline or ciprofloxacin. There were no significant 
differences in serum folate, erythrocyte folate and small intestinal mucosal folate levels among 
the four animal groups (data shown in detail in the original article). However, folate levels of 
colonic mucosa were significantly reduced in the ethanol-treated group 3, by approximately 
50% in comparison to the other three groups (Fig. 4). 
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 Fig. 4. Colonic acetaldehyde and folate levels in the study groups (mean ± SEM). P value refers to the   
corresponding bars of groups 1, 2, and 4.  (Reproduced with permisson from Int J Cancer). 
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5.7. FACTORS INFLUENCING SALIVARY ACETALDEHYDE PRODUCTION IN 
HUMANS (V) 
 
The various regression analyses clearly showed that smoking and heavy alcohol intake are 
powerful predictors of microbial acetaldehyde production. As these factors themselves showed 
colinearity, analysis was repeated for all non-smokers (n=189) to estimate the influence 
attributable to alcohol intake alone, and for subjects with only moderate or no alcohol 
consumption to estimate the influence of smoking alone (n=259). This analysis method 
demonstrated that both were independent risk factors of higher salivary acetaldehyde 
production. Smoking and heavy alcohol consumption increased the salivary acetaldehyde 
production in comparison to the control groups by 60-75%, and combined misuse further 
increased it (Fig. 5).  
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 Fig. 5. Salivary acetaldehyde production in correlation with smoking and drinking. * p < 0.05   
 versus non-smokers, moderate alcohol consumption. (Reproduced with permission from 
 Carcinogenesis). 
 
 
Age (inverse correlation, r=-0.13, p=0.02) and the reported frequency of dry mouth (positive 
correlation, r=0.1, p=0.06) were other, less compelling factors possibly associated with 
increased acetaldehyde production. Dry mouth also showed co-linearity with smoking and 
alcohol intake. After adjustment for confounders, the reported frequency of a dry mouth 
showed a slight but significant contribution to salivary acetaldehyde production, at least in 
non-smokers. It can be estimated that a subject with very frequent complaints of a dry mouth 
has approximately 20% higher salivary acetaldehyde levels than subjects without such 
symptoms. 
   
None of the other variables contributed significantly to salivary acetaldehyde production. 
Patients with cancer of the oral cavity did not have salivary acetaldehyde production which 
differed significantly from the rest of the cohort. This was true both for patients with fresh, 
untreated tumours as for patients in follow-up after surgical operation. Patient characteristics 
and statistical analysis are shown in detail in the original article. 
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5.8. MICROBES ASSOCIATED WITH ACETALDEHYDE PRODUCTION IN THE 
HUMAN ORAL CAVITY (V, VI) 
   
Microbial analysis of the ten saliva samples with the highest and ten with the lowest 
acetaldehyde production capacity showed a clear increase in the total count of aerobes among 
"high" producers. Aerobic species that were significantly associated with higher acetaldehyde 
production were Streptococcus salivarius, the hemolytic viridans group Streptococci, 
Corynebacterium sp., Stomatococcus sp. and yeasts. No bacterial species were found to be 
significantly more frequent in the saliva of "low" acetaldehyde producers. Yeasts were not only 
found at higher concentrations but also more frequently among the ten subjects with high 
acetaldehyde production  (8 of 10 versus 2 of 10, p=0.02). 
 
Since this analyses revealed that the presence of yeasts could be an important microbiological 
factor  that may determine an individual’s capacity to produce acetaldehyde from ethanol in 
saliva, yeasts were isolated from all the saliva samples that produced acetaldehyde of more 
than 250 µM and less than 40 µM. Yeasts colonization was found in 78% of the high 
acetaldehyde-producing salivas, compared with 47% in the low acetaldehyde-producing 
salivas (p = 0.026). Among the yeast carriers, the number of isolated strains per subject were 
similar in both groups. However, the density of yeasts was higher in high than in low 
producers (p = 0.025). 
 
Of the 55 subjects, 8 were heavy users of both tobacco (15 to 40 cigarettes/day, mean 23) and 
alcohol (78 to 150 g/day, mean 112 g). All of these saliva samples belonged to the high 
acetaldehyde producing group, and the presence of yeasts in this group was statistically 
significant compared to the group of non-smokers and moderate (<30 grams per day) or non-
drinkers (n=20) (100% in smokers/drinkers vs 45% in controls, p=0.0097). Moreover, the 
yeast counts were higher in the group of smokers/drinkers than the controls (1.8 ± 1.3 x105 
CFU/ml vs. 3.1 ± 2.6 x 104 CFU/ml, p=0.0081).  
   
Each of the yeast species isolated were able to produce acetaldehyde from ethanol in vitro, and 
the acetaldehyde production capacity was in proportion to the length of the incubation, the 
quantity of yeasts, and the concentration of ethanol. However, there was a 180-fold difference 
in the acetaldehyde production capacity between the strains over 60 min of incubation, ranging 
from 1.3 nmol ach/106 CFU to 236.4 nmol ach/106 CFU (Strain dependent data shown in 
detail in the original article).  
 
Candida albicans was the dominating yeast species in both groups, constituting 88% of all oral 
isolates (87% and 90% among the high and low producing salivas respectively). Moreover, C. 
albicans strains isolated from the high acetaldehyde-producing salivas produced significantly 
higher acetaldehyde levels from ethanol than C. albicans strains from low acetaldehyde 
producing salivas (73.1 nmol ach/106 CFU vs. 43.2 nmol ach/106 CFU, p = 0.035).  
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6. DISCUSSION 
 
6.1. ROLE OF CATALASE IN ACETALDEHYDE PRODUCTION BY COLONIC 
CONTENTS 
 
Under microaerophilic or aerobic conditions and in the presence of excess ethanol, some 
microorganisms can oxidize ethanol to acetaldehyde. In the past this bacteriocolonic pathway 
for ethanol oxidation was primarily thought to be mediated via reversed microbial ADH 
reaction (Jokelainen et al., 1996a). However, some members of the Enterobacteriaceae family 
appear to produce considerable amounts of acetaldehyde from ethanol with minimal ADH 
activity (Jokelainen et al., 1996a). This raised the question of whether enzymes other than 
ADH also participate in bacterial acetaldehyde production. A good explanation of this may be 
the existence of catalase in these bacteria. 
 
The enzyme catalase is, indeed, present in most cytochrome-containing aerobic and facultative 
anaerobic bacteria, and only strict anaerobes lack this enzyme (Deisseroth and Dounce, 1970). 
For example, members of the Enterobacteriaceae family like Escherichia coli, Klebsiella 
pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Hafnia alvei (Chester and Moskowits, 
1987), as well as Helicobacter pylori (Hazell et al., 1991) and a number of yeasts (Fukui et al., 
1975; Tosado-Acevedo et al., 1992) have been shown to possess catalase activity. The 
physiological role of catalase in bacteria is to protect aerobes and aerotolerant anaerobes from 
the toxicity of oxygen, resulting from its reduction to hydrogen peroxide (H2O2). Catalase 
protects bacteria by catalysing the reaction: 2H2O2   2H2O + O2 (Fukui et al., 1975). In 
addition to catalysing the breakdown of H2O2 (catalatic activity) the enzyme also has another 
function. In the presence of low concentrations of H2O2, it is able to oxidize electron donors 
(peroxidatic activity) (Percy, 1984). In the case of ethanol, this reaction yields acetaldehyde 
(Oshino et al., 1973). Because catalase has two enzymatic functions it is possible that catalase 
may react either catalatically or peroxidatically depending on the microenvironment of the 
bacterial cells.   
 
In this study acetaldehyde production by human colonic contents was inhibited by catalase 
inhibitors, sodium azide and 3 -amino-1,2,4-triazole, but not with cytochrome P-450 inhibitor, 
metyrapone, or the alcohol dehydrogenase inhibitor, 4-methylpyrazole. The poor inhibitory 
effect of 4-MP can be explained by its low efficacy on microbial ADHs. Another possibility is 
that the amount of NAD in lyophilizised contents or inside colonic bacteria is so slight that the 
microbial ADHs are not able to take part in the bacterial acetaldehyde production from ethanol 
under these in vitro conditions. The fact that acetaldehyde production was markedly increased 
after the addition of exogenous NAD is in favour of the latter possibility. 
 
The amount of acetaldehyde produced increased in the presence of both exogenous NAD or 
the H2O2 producing system.  Thus in colonic contents there are at least two enzyme systems 
that can produce acetaldehyde from ethanol. The aspirated colonic contents are a mixture of 
electrolyte solution, sloughed mucosal cells, and mainly colonic bacteria. Moreover, since 
lyophilization has been used as a gentle method for the preservation of biological material, 
particularly proteins, the enzymes that participate in acetaldehyde production are probably of 
bacterial origin. Our findings indicate that in addition to microbial alcohol dehydrogenase, 
microbial catalase may also participate in bacterial ethanol metabolism and acetaldehyde 
production in the colon.  
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6.2. ROLE OF COLONIC BACTERIA IN EXTRAHEPATIC ETHANOL 
ELIMINATION IN HUMANS 
 
The most important route of ethanol elimination is its metabolism in the liver, and only about 
one percent is excreted unmetabolised (Holford, 1987). However, extrahepatic elimination of 
ethanol occurs as well. In rats, the extrahepatic gastrointestinal metabolism of circulating 
ethanol has been shown to be up to 30% of that in the liver (Huang et al., 1993) and in patients 
with cirrhosis of the liver, extrahepatic elimination has been estimated to constitute about 40% 
of the total ethanol elimination (Utne and Winkler, 1980). Our previous studies show that 
bacterial ethanol metabolism in the large intestine may be one of the major extrahepatic 
pathways for ethanol oxidation (Jokelainen et al., 1997). 
  
This study showed that one week’s treatment with ciprofloxacin reduces the ethanol 
elimination rate in humans by 9.4%. No change in peak ethanol concentration or volume of 
distribution was detected. The intravenous administration of ethanol excludes the possible 
effects of altered gastric emptying and gastric first-pass metabolism on ethanol 
pharmacokinetics (Fraser, 1997). Ciprofloxacin did not inhibit hepatic ADH activity in vitro in 
concentrations known to exist in the liver tissue during treatment (Dan et al., 1987). It has, 
however, been reported to reduce the hepatic metabolism of coadministered xanthines, such as 
theophylline and caffeine, leading to increased serum concentrations and reduced elimination 
of these substances (Radandt et al., 1992). The mechanism behind this effect is the inhibition 
of CYP1A2 activity (Mizuki et al., 1996). CYP1A2 has been shown to be able to metabolise 
ethanol in MEOS, although the major contributor to the MEOS in humans is the isoenzyme 
CYP2E1 (Asai et al., 1996). Thus the inhibitory effect of ciprofloxacin on the EER could at 
least partly be the consequence of the drug’s interference with cytochrome mediated ethanol 
oxidation. Since the contribution of the MEOS to ethanol metabolism, however, is at most 5% 
(Ingelman-Sundberg, 1997), the interactions between ciprofloxacin and ethanol oxidizing 
enzymes in the liver probably explain only a small part of the reduction in the ethanol 
elimination rate. Hepatic metabolism of ethanol may also be reduced because of the changes in 
hepatic blood flow. Ciprofloxacin, however, has no effect on the clearance of indocyanine 
green, a dye largely extracted by the liver, which indicates the lack of any effect on hepatic 
blood flow (Nix et al., 1987). Thus the decrease in ethanol elimination found in this study is 
unlikely to be the result of decreased hepatic blood flow. 
 
This study is also in line with our previous findings with rats. Jokelainen et al. (1997) reported 
a 9% (p<0.02) reduction in ethanol elimination in rats after four days’ high dose ciprofloxacin 
treatment, with a concomitant decrease in faecal aerobic bacteria and ADH activity. The 
results of this study suggest that the decrease in the ethanol elimination produced by 
ciprofloxacin is at least partly due to the reduction of gut aerobic flora and the consequent 
inhibition of ethanol oxidation via colonic bacteria.  
 
The findings from the faecal analysis support this hypothesis. In this study ciprofloxacin 
treatment showed a tendency to decrease aerobic flora, with only small changes in the 
anaerobic bacteria. Anaerobes that were only slightly affected were Bifidobacterium sp. The 
marked change was the complete suppression of the Enterobacteriaceae, which was the 
predomint species before the medication. Enterococcus sp., initially present in 63% of 
volunteers, also disappeared. The other aerobic species responded variably, and slight 
overgrowth of yeasts occurred only in two volunteers of eight. The bacteriological changes in 
faecal flora induced by ciprofloxacin are well in line with the previous studies (Campoli-
Richards et al., 1988). 
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This is the first study to show that human stool samples possess ADH and catalase activity and 
to produce acetaldehyde from ethanol in vitro. The faecal ADH activity and acetaldehyde 
production  capacity decreased significantly after one week’s ciprofloxacin treatment, whereas 
catalase activity remained unaltered. Furthermore, there was a significant correlation between 
faecal ADH activity and acetaldehyde production. Since Enterobacteriaceae has been shown 
to produce acetaldehyde from ethanol in vitro (Jokelainen et al., 1996a), these findings suggest 
that ethanol oxidation by colonic bacteria in man is probably mediated by Enterobacteriaceae 
and ADH-associated reactions.  
   
 
6.3. THE EFFECT OF LONG-TERM ETHANOL AND METRONIDAZOLE 
TREATMENT ON INTRACOLONIC ACETALDEHYDE LEVELS  
 
In the present study, alcohol treatment for 6 weeks led to elevated intracolonic acetaldehyde 
levels. Acetaldehyde production was further increased 5-fold after metronidazole treatment. 
Since metronidazole has been shown to increase the number of aerobic bacteria in the large 
intestine at the expense of the number of strict anaerobes both in experimental animals and 
humans (Brook and Ledney, 1994; Krook, 1981), it is an effective drug against anaerobic 
bacteria. This was also confirmed by our study, the total count of aerobes and especially that of 
Enterobacteriaceae and Staphylococcus species being significantly higher in the caecal 
contents of the metronidazole-treated rats than among their corresponding controls. Since 
metronidazole treatment did not inhibit the ALDH activity of the colonic mucosa, the increase 
in intracolonic acetaldehyde production from ethanol can be explained by the replacement of 
intestinal anaerobes by ADH-containing facultative Enterobacteriaceae. These results indicate 
the significance of these Gram-negative bacteria in ethanol oxidation and acetaldehyde 
production in the large intestine.  
   
We have previously shown marked intracolonic acetaldehyde production from ethanol in 
experimental animals after a single dose of ethanol (Jokelainen et al., 1996c; Visapää et al., 
1998). This is the first study to show that intracolonic acetaldehyde levels also remain high 
during long-term ethanol intake, indicating that colonic mucosa or bacteria do not adapt, at 
least not completely, to removing toxic acetaldehyde during chronic ethanol intoxication. 
However, adaptation might occur to a certain extent since colonic mucosal ALDH activity was 
significantly higher in the rats receiving ethanol and metronidazole than in the ethanol treated 
rats. On the other hand, the quantitative and qualitative changes in the intestinal microflora 
after long-term ethanol intake, i.e. the increase in the number of Enterobacteriaceae as shown 
in this study, may increase microbial acetaldehyde production. Acetaldehyde accumulation 
inside the large intestine has been related to the low ALDH activity of the colonic mucosa and 
intestinal bacteria (Koivisto and Salaspuro, 1996; Nosova et al., 1996). In this study colonic 
mucosal ALDH activities were four times lower than in the liver, supporting the previous 
concept. 
 
Acetaldehyde concentrations in the colon are much higher than in the liver, but the 
pathogenetic role of intracolonic acetaldehyde remains still, at least partly, uncertain. Since 
ciprofloxacin treatment has been shown to decrease intracolonic microbially-derived 
acetaldehyde production from ethanol (Visapää et al., 1998) and metronidazole increases it, 
these treatment models can be used as a tool to investigate gastrointestinal morbidity 
associated with alcohol and high intracolonic acetaldehyde production. 
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6.4. THE EFFECT OF ETHANOL AND METRONIDAZOLE TREATMENT ON 
HEPATIC ETHANOL AND ACETALDEHYDE METABOLISM 
 
Metronidazole did not inhibit hepatic ALDH or ADH activity. Furthermore, blood ethanol and 
acetaldehyde levels were similar in ethanol and ethanol and metronidazole receiving rat 
groups. These findings suggest that metronidazole treatment has no significant effect on 
ethanol metabolism in the rats. This is interesting, since some case-reports and uncontrolled 
studies with metronidazole identify disulfiram-like symptoms when taken with ethanol 
(Alexander, 1985; Goodwin and Reinhard, 1972; Lehmann et al., 1966; Strassman et al., 
1970). Disulfiram itself blocks hepatic low-Km aldehyde dehydrogenase, which leads to 
increased blood acetaldehyde levels if used with ethanol. This causes unpleasant symptoms, 
flushing, palpitations, headache, nausea, and sometimes vomiting (Peachey and Sellers, 1981). 
The mechanism behind metronidazole related disulfiram-like reaction has been thought to be 
similar to that of disulfiram (Lau et al., 1992). However, others have shown that metronidazole 
does not increase blood acetaldehyde levels or inhibit ALDH in rats (Kalant et al., 1972; 
Vasiliou et al., 1986). Since these findings were confirmed in the present study, there is no 
proper explanation for the reported disulfiram-like effects of metronidazole after alcohol 
intake. The existence of metronidazole and alcohol interaction is also called into question in 
two very recent review articles (Garey and Rodvold, 1999; Williams and Woodcock, 2000). 
Despite this, patients should be advised not to consume these two agents together.  
   
Other antimicrobial agents which may have disulfiram-like effects include beta-lactams, e.g. 
cephamandole, cefoperazone and moxalactam, with N-methyltetrazolylthiomethyl groups at 
the 3-position of the cephalosporin nucleus (Buening et al., 1981; Matsubara et al., 1987; Uri 
and Parks, 1983). These drugs have been shown to inhibit liver ALDH activity and to increase 
the levels of acetaldehyde in the blood after ethanol intake, leading to a real disulfiram-like 
reaction. Our study implies that reported disulfiram-like effects caused by metronidazole and 
alcohol intake might develop in a different way. One explanation could be the high 
intracolonic acetaldehyde formation from ethanol after metronidazole treatment. At the 
periphery, acetaldehyde levels comparable to those found in this study have been shown to 
induce histamine release from purified Mast cells (Koivisto et al., 1999) and to depress 
histamine elimination, resulting in elevated histamine levels in tissues (Zimatkin and 
Anichtchik, 1999). Thus, it is possible that acetaldehyde-induced histamine release may 
contribute to various hypersensitivity reactions caused by alcohol ingestion. This is supported 
by findings that histamine can mediate the acetaldehyde-induced flushing reaction. Elevated 
plasma histamine levels following the administration of histamine correlate well with clinical 
symptoms resembling the alcohol-induced flushing in orientals (Zimatkin and Anichtchik, 
1999). Thus, it may hypothetically be that the mechanism producing the metronidazole related 
disulfiram-like effects associated with alcohol intake are rather located in the large intestine 
microflora’s capacity to produce acetaldehyde than in the liver. 
   
There is no data suggesting whether metronidazole inhibits human hepatic ALDH activity. In 
humans and rats the isoenzyme mainly responsible for the oxidation of ethanol-derived 
acetaldehyde is hepatic mitochondrial ALDH2. Noteworthy, however, is nitrefazole’s ability to 
cause a disulfiram-like reaction with elevated blood acetaldehyde level, flushing, tachycardia, 
and hypotension after ethanol ingestion (Suokas et al., 1985). Nitrefazole is structurally related 
to metronidazole, except that the nitro group in nitrefazole is in position 4 of the imidazole 
ring, whereas metronidazole is mainly substituted in position 5 (Klink et al., 1985). It has been 
shown to cause a strong and long-lasting inhibition of hepatic mitochondrial ALDH (Klink et 
al., 1985). The structural differences between metronidazole and nitrefazole may generate 
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dissimilarities in their ALDH inhibitory potential as with various beta-lactams. There is 
evidence that hepatic ALDH2 in rats differs in its sensitivity to disulfiram and nitrefazole 
compared to the human one, although both drugs inhibit it in both species (Zorzano and 
Herrera, 1990); thus it is possible that human and rat liver ALDHs differ in their sensitivity to 
the inhibitory effect of metronidazole as well. One must therefore be cautious in extrapolating 
the past and present results obtained with rats to human subjects. 
   
 
6.5. THE EFFECT OF ACETALDEHYDE ON INTESTINAL FOLATE LEVELS IN 
RATS - A POSSIBLE CARCINOGENIC ACTION OF ACETALDEHYDE  
 
High alcohol and low folate intake are independent risk factors for colorectal carcinogenesis 
(Giovannucci et al., 1995; Kune and Vitetta, 1992; Longnecker et al., 1990). It has been 
suggested that folate deficiency enhances colorectal neoplasia by depleting labile methyl 
groups and by inducing DNA hypomethylation (Cravo et al., 1992). Acetaldehyde, a known 
carcinogen, has been postulated to be a factor possibly responsible for ethanol-associated 
carcinogenesis, since high levels accumulate in the large intestine through the microbial 
oxidation of alcohol (Salaspuro, 1996, 1997). Moreover, if high alcohol intake and low-folate 
diet are observed, the attributable relative risk of colon cancer increases synergistically in a 
multiplicative manner, while in individuals with supraphysiological folate repletion, no 
elevated cancer risk from alcohol is observed (Boutron-Ruault et al., 1996; Giovannucci et al., 
1995). Increased alcohol intake and a low-folate diet thus exert a synergistic effect on 
colorectal carcinogenesis, and are influenced by each other (Anonymous, 1994). 
 
One explanation for this could be the high intracolonic acetaldehyde levels formed after 
ethanol administration, since it has been shown that high acetaldehyde levels can cleave folate 
to inactive forms via acetaldehyde/xanthine oxidase-generated superoxide (Shaw et al., 1989). 
This interesting in vitro mechanism, by which alcohol leads to folate deficiency, has often 
been considered insignificant in vivo as the concentrations of acetaldehyde have been thought 
to be too low. However, as shown in this study, the local intracolonic acetaldehyde levels may 
reach the required level. Low vapour pressure and high water solubility (Matysiak-Budnik et 
al., 1996) enable most acetaldehyde in the colonic lumen to reach the colonic mucosa (Seitz et 
al., 1990). The observed decreased folate levels of colonic mucosa in ethanol-treated rats are 
thus probably caused by the cleavage of folate through high intracolonic levels of acetaldehyde 
produced from ethanol by gut microbes. 
 
The involvement of high colonic acetaldehyde in local folate decrease is also supported by the 
fact that the effect of alcohol on mucosal folate levels was effectively attenuated by a 
concomitant treatment with ciprofloxacin, which reduced the intracolonic acetaldehyde levels 
to 5% of that found after treatment with alcohol alone. Moreover, acetaldehyde levels in the 
small intestine were very low, and only the folate level of the colonic mucosa, not small 
intestinal mucosa, was decreased by alcohol. Low acetaldehyde in the small intestine can be 
explained by the fact that small intestine is colonized by fewer bacteria than the large intestine 
(Rowland, 1986). As indicated by normal serum folate levels and by the sufficient folate 
uptake of the rats treated with ethanol decreased nutritional intake cannot explain our findings. 
Mechanisms other than this antimicrobial effect of ciprofloxacin on acetaldehyde production 
from ethanol are unlikely to play a significant role, as there were no differences in the colonic 
folate levels between the control-saline group and the control-ciprofloxacin group.  
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6.6. ACETALDEHYDE IN SALIVA: INFLUENCING FACTORS 
 
Although alcohol and tobacco smoke are well-known independent risk factors for upper 
gastrointestinal tract cancer, their combined action on these epithelia has remained poorly 
understood. There is epidemiological evidence indicating that alcohol and tobacco act together 
in a multiplicative rather than additive manner and, accordingly, seem to have synergistic 
tumor-promoting effects (La Vecchia et al., 1997). As alcohol is involved synergistically in the 
attributable risk of both smoking and poor oral hygiene, it is conceivable that there may be a 
unifying pathogenetic mechanism  behind these epidemiological findings. This may be the 
local production of carcinogenic acetaldehyde from ethanol by oral microbes. Salivary 
acetaldehyde may reach all target tissues of the upper aerodigestive tract, including the larynx, 
pharynx, oral cavity, and esophagus, via normal distribution and evaporation. 
 
In the present study, we were able to demonstrate that smoking and heavy alcohol 
consumption significantly increase salivary acetaldehyde production. Smoking showed a 
positive linear correlation and it can be estimated that a smoker with a daily consumption of 
approximately twenty cigarettes has an increased salivary acetaldehyde production of about 
50-60%. This implies that smokers, even after moderate alcohol intake, produce much higher 
levels of carcinogenic acetaldehyde in the oral cavity than non-smokers. The evidence for 
increased microbial salivary acetaldehyde production in smokers, together with the 
epidemiological description of the multiplicative carcinogenic action of alcohol and smoking, 
suggests that the salivary acetaldehyde production mediated by microbes could be the 
biologically plausible pathogenetic mechanism for these findings. Alcohol seems to interact 
and increase salivary acetaldehyde production only if consumed heavily; when an increase is 
observed it is dose dependent. Smoking and alcohol together increase the salivary 
acetaldehyde production by about 100% as compared to non-smokers and moderate alcohol 
consumers.  
 
 
6.7. MICROBES ASSOCIATED WITH ACETALDEHYDE PRODUCTION IN THE 
HUMAN ORAL CAVITY 
 
As stated above, one possible pathogenetic explanation underlying the joint effect of tobacco 
smoking and alcohol drinking on oropharyngeal carcinogenesis could be the increased local 
production of acetaldehyde from ethanol by oral microbes. This however could also be due to 
an altered oral microflora producing more acetaldehyde.  
 
This theory is supported by the literature and our results. Smoking has been shown to increase 
the number of yeasts in the oral flora (Sakki and Knuuttila, 1996). In general, a microbial 
"switch" with a significant increase in the proportion of Gram-positive versus Gram-negative 
bacteria has been described in smokers (Colman et al., 1976; Macgregor, 1988), whereas 
Neisseriae spp. have been reported to occur less frequently in the oral cavity of smokers 
(Colman et al., 1976). Although, microbial changes in the oral microflora of alcoholics have 
not been described, slight immunodeficiency associated with alcoholism together with poor 
oral hygiene and nutritional defects may favour the growth of bacteria and Candida albicans in 
the oral cavity (MacGregor, 1986; Oksala, 1990). These are well in line with our observation 
that almost all aerobic Gram-positive bacteria were significantly increased in "high" 
acetaldehyde producers (the facultative commensals Staphylococcus sp. and Streptococcus 
mutans being the only exceptions), whereas the Gram-negative aerobic bacteria, Haemophilus 
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sp. and the already-mentioned Neisseria sp. were not associated with higher acetaldehyde 
production. Thus, there is in general a good link between our microbial observations that some 
species are associated with higher acetaldehyde production and the well-known effect of 
smoking on the oral microflora.      
 
Moreover, our microbial analyses revealed that yeasts (and possibly Corynebacterium sp.) 
were found in higher loads and more frequently in the high acetaldehyde-producing saliva 
group than the low group. Since Candida albicans was the dominating yeast species isolated 
from the saliva and C. albicans produced on average higher acetaldehyde levels than other 
yeast species detected, this can be regarded as the most common and important yeasts species 
with respect to acetaldehyde production capacity from ethanol. This is further supported by the 
finding that C. albicans strains isolated from the high acetaldehyde-producing salivas formed 
significantly higher acetaldehyde levels than those isolated from the low acetaldehyde-
producing salivas. 
 
C. albicans is an aerobic microorganism exhibiting ADH activity and it is closely 
associated with mucosal membranes. C. albicans colonization is also often present in the 
case of oral cancer, but whether these yeasts are causally involved in the development of 
this cancer is still not clear (Krogh et al., 1987; Sciubba, 1995). Oral leukoplakia is a 
premalignant transformation often invaded by yeasts, and if untreated 5-10% of the cases will 
develop into carcinoma. C. albicans infection together with simultaneous existence of several 
etiological factors seem to play a role in the malignant transformation (Banoczy, 1977; Krogh 
et al., 1987). It has been hypothesized that certain Candida types from oral leukoplakia have 
higher nitrosation potential than others, which might indicate the involvement of specific yeast 
types in the transformation of leukoplakia into carcinoma (Krogh et al., 1987). In the light of 
our hypothesis, an additional plausible etiological explanation could be alcohol drinking and 
consequent high acetaldehyde production via reversed ADH-mediated reaction by certain 
Candida albicans strains.  
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7. SUMMARY AND CONCLUSION 
 
 
The key findings of the present study were: 
 
1. These in vitro results demonstrate that in addition to alcohol dehydrogenase (ADH), colonic 
contents and faeces exhibit catalase activity, which probably is of bacterial origin. This 
indicates that part of the acetaldehyde produced in the large intestine via the bacteriocolonic 
pathway for ethanol oxidation may be catalase dependent. However, it is probable that the role 
of catalase-dependent acetaldehyde production by large intestinal microflora is limited, and the 
main source of acetaldehyde is via the reversed ADH reaction. 
 
2. Ciprofloxacin treatment decreases the ethanol elimination rate by a mean of 9.4% in man, 
with a concomitant decrease in faecal ADH activity and acetaldehyde production in vitro. 
Since there is no evidence that ciprofloxacin interferes with hepatic ethanol metabolism, our 
findings can be explained by the reduction of aerobic and facultative anaerobic bacteria in the 
lumen and mucosal surfaces of the human large intestine. These findings support the evidence 
for colonic bacteria having a significant, and at least approximately 10%  role in the 
extrahepatic ethanol elimination in humans. 
 
3. Ciprofloxacin treatment effectively reduced the intracolonic acetaldehyde production from 
ethanol in rats to 5% of that found after treatment with ethanol alone. In the human study, 
ciprofloxacin effectively eradicated Enterobacteriaceae from the stool and reduced faecal 
ADH activity. Before medication these bacteria were the main aerobic species in the faeces, 
and it has previously been shown that isolated Enterobacteriaceae are able to produce 
acetaldehyde from ethanol in a reaction catalysed by bacterial ADH in vitro. Moreover, 
metronidazole and ethanol treatment of rats increased acetaldehyde production in the large 
intestine to 5 times that of rats treated with ethanol only. Since this was associated with an 
increase in caecal aerobic flora, especially Enterobacteriaceae and Streptococcus species, it 
can be concluded that facultative Gram-negative Enterobacteriaceae are probably responsible 
for acetaldehyde production in the large intestine. 
 
4. We have already demonstrated intracolonic acetaldehyde production from ethanol in 
experimental animals after a single dose of ethanol. Our previous results show that 
intracolonic acetaldehyde levels also remain high during long-term ethanol intake. This 
indicates that colonic mucosa or bacteria do not adapt to remove acetaldehyde during long-
term ethanol intoxication. Since acetaldehyde is toxic and carcinogenic, the knowledge that 
acetaldehyde levels remain high even after long-term alcohol use implies that microbially 
produced acetaldehyde may play a role in the gastrointestinal symptoms and morbidity 
associated with chronic alcohol use. 
 
 5. High alcohol intake leads to local folate deficiency in rat colonic mucosa, probably via the 
high levels of microbially produced acetaldehyde. Our preliminary results suggest that 
microbial production of acetaldehyde from ethanol also occurs in vivo in the human colon. 
Accordingly, these results suggest a possible mechanism by which the unique and synergistic 
effects of high alcohol and low folate intake on colorectal carcinogenesis might be explained.   
 
6. Tobacco smoking and alcohol consumption are the most potent external risk factors for 
upper digestive tract cancer. In this study we demonstrated an increased microbial salivary 
acetaldehyde production associated with these conditions. Moreover, our results demonstrate 
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that almost all aerobic Gram-positive bacteria and Candida albicans were found in 
significantly higher numbers in the saliva among high acetaldehyde producers. Numerous 
studies support the hypothesis that acetaldehyde is the substance behind the tumor-promoting 
effect of alcohol on the mucosa of the oral cavity. Our findings thus provide a biologically 
plausible mechanism for the synergistic and multiplicative manner in which the attributable 
cancer risks of alcohol and smoking act. 
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